PharmGKB ID,Literature,Variant,Drug,Class,activity_score,Association,isomeric,phenotype
1451153742,PMID:11270921,CYP2D6.4.001; CYP2D6.6.001,(R)-methadone,f,0,CYP2D6 *4/*6 are associated with increased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer genotype phenotype) .,CCC(=O)C(C[C@@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,CYP2D6 Poor Metabolizer
1451153742,PMID:11270921,CYP2D6.1.001; CYP2D6.1.001,(R)-methadone,nor,2,CYP2D6 *3/*4 are associated with increased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer genotype phenotype) .,CCC(=O)C(C[C@@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,CYP2D6 Normal Metabolizer
1451153742,PMID:11270921,CYP2D6.3.001; CYP2D6.4.001,(R)-methadone,f,0,CYP2D6 *3/*4 are associated with increased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer genotype phenotype) .,CCC(=O)C(C[C@@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,CYP2D6 Poor Metabolizer
1451153742,PMID:11270921,CYP2D6.1.001; CYP2D6.5.001,(R)-methadone,nor,1,CYP2D6 *3/*4 are associated with increased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer genotype phenotype) .,CCC(=O)C(C[C@@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,CYP2D6 Intermediate Metabolizer
1451153742,PMID:11270921,CYP2D6.1.001; CYP2D6.6.001,(R)-methadone,nor,1,CYP2D6 *3/*4 are associated with increased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer genotype phenotype) .,CCC(=O)C(C[C@@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,CYP2D6 Intermediate Metabolizer
1451153742,PMID:11270921,CYP2D6.1.001; CYP2D6.3.001,(R)-methadone,nor,1,CYP2D6 *3/*4 are associated with increased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer genotype phenotype) .,CCC(=O)C(C[C@@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,CYP2D6 Intermediate Metabolizer
1451153742,PMID:11270921,CYP2D6.1.001; CYP2D6.5.001,(S)-methadone,nor,1,CYP2D6 *3/*4 are associated with increased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer genotype phenotype) .,CCC(=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,CYP2D6 Intermediate Metabolizer
1451153742,PMID:11270921,CYP2D6.1.001; CYP2D6.3.001,(S)-methadone,nor,1,CYP2D6 *3/*4 are associated with increased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer genotype phenotype) .,CCC(=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,CYP2D6 Intermediate Metabolizer
1451153742,PMID:11270921,CYP2D6.4.001; CYP2D6.6.001,(S)-methadone,f,0,CYP2D6 *4/*6 are associated with increased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer genotype phenotype) .,CCC(=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,CYP2D6 Poor Metabolizer
1451153742,PMID:11270921,CYP2D6.1.001; CYP2D6.6.001,(S)-methadone,nor,1,CYP2D6 *3/*4 are associated with increased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer genotype phenotype) .,CCC(=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,CYP2D6 Intermediate Metabolizer
1451153742,PMID:11270921,CYP2D6.1.001; CYP2D6.1.001,(S)-methadone,nor,2,CYP2D6 *3/*4 are associated with increased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer genotype phenotype) .,CCC(=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,CYP2D6 Normal Metabolizer
1451153742,PMID:11270921,CYP2D6.3.001; CYP2D6.4.001,(S)-methadone,f,0,CYP2D6 *3/*4 are associated with increased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer genotype phenotype) .,CCC(=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,CYP2D6 Poor Metabolizer
1448109032,PMCID:PMC4949007,CYP2D6.2.001; CYP2D6.2.001,"3,4-methylenedioxymethamphetamine",nor,2,"CYP2D6 *4/*4  is associated with decreased metabolism of 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.",CC(CC1=CC2=C(C=C1)OCO2)NC,CYP2D6 Normal Metabolizer
1448109032,PMCID:PMC4949007,CYP2D6.1.001; CYP2D6.41.001,"3,4-methylenedioxymethamphetamine",nor,1.25,"CYP2D6 *4/*4  is associated with decreased metabolism of 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.",CC(CC1=CC2=C(C=C1)OCO2)NC,CYP2D6 Normal Metabolizer
1448109032,PMCID:PMC4949007,CYP2D6.1.001; CYP2D6.2.001,"3,4-methylenedioxymethamphetamine",nor,2,"CYP2D6 *4/*4  is associated with decreased metabolism of 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.",CC(CC1=CC2=C(C=C1)OCO2)NC,CYP2D6 Normal Metabolizer
1448109032,PMCID:PMC4949007,CYP2D6.5.001; CYP2D6.41.001,"3,4-methylenedioxymethamphetamine",de,0.25,"CYP2D6 *4/*4  is associated with decreased metabolism of 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.",CC(CC1=CC2=C(C=C1)OCO2)NC,CYP2D6 Intermediate Metabolizer
1448109032,PMCID:PMC4949007,CYP2D6.9.001; CYP2D6.10.001,"3,4-methylenedioxymethamphetamine",nor,0.5,"CYP2D6 *4/*4  is associated with decreased metabolism of 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.",CC(CC1=CC2=C(C=C1)OCO2)NC,CYP2D6 Intermediate Metabolizer
1448109032,PMCID:PMC4949007,CYP2D6.1.001; CYP2D6.3.001,"3,4-methylenedioxymethamphetamine",nor,1,"CYP2D6 *4/*4  is associated with decreased metabolism of 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.",CC(CC1=CC2=C(C=C1)OCO2)NC,CYP2D6 Intermediate Metabolizer
1448109032,PMCID:PMC4949007,CYP2D6.1.001; CYP2D6.9.001,"3,4-methylenedioxymethamphetamine",nor,1.25,"CYP2D6 *4/*4  is associated with decreased metabolism of 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.",CC(CC1=CC2=C(C=C1)OCO2)NC,CYP2D6 Normal Metabolizer
1448109032,PMCID:PMC4949007,CYP2D6.1.001; CYP2D6.4.001,"3,4-methylenedioxymethamphetamine",nor,1,"CYP2D6 *4/*4  is associated with decreased metabolism of 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.",CC(CC1=CC2=C(C=C1)OCO2)NC,CYP2D6 Intermediate Metabolizer
1448109032,PMCID:PMC4949007,CYP2D6.1.001; CYP2D6.1.001,"3,4-methylenedioxymethamphetamine",nor,2,"CYP2D6 *4/*4  is associated with decreased metabolism of 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.",CC(CC1=CC2=C(C=C1)OCO2)NC,CYP2D6 Normal Metabolizer
1448109032,PMCID:PMC4949007,CYP2D6.10.001; CYP2D6.2.001,"3,4-methylenedioxymethamphetamine",nor,1.25,"CYP2D6 *4/*4  is associated with decreased metabolism of 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.",CC(CC1=CC2=C(C=C1)OCO2)NC,CYP2D6 Normal Metabolizer
1448109032,PMCID:PMC4949007,CYP2D6.3.001; CYP2D6.3.001,"3,4-methylenedioxymethamphetamine",f,0,"CYP2D6 *4/*4  is associated with decreased metabolism of 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.",CC(CC1=CC2=C(C=C1)OCO2)NC,CYP2D6 Poor Metabolizer
1448109032,PMCID:PMC4949007,CYP2D6.4.001; CYP2D6.9.001,"3,4-methylenedioxymethamphetamine",de,0.25,"CYP2D6 *4/*4  is associated with decreased metabolism of 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.",CC(CC1=CC2=C(C=C1)OCO2)NC,CYP2D6 Intermediate Metabolizer
1448109032,PMCID:PMC4949007,CYP2D6.4.001; CYP2D6.4.001,"3,4-methylenedioxymethamphetamine",f,0,"CYP2D6 *4/*4  is associated with decreased metabolism of 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.",CC(CC1=CC2=C(C=C1)OCO2)NC,CYP2D6 Poor Metabolizer
1448109032,PMCID:PMC4949007,CYP2D6.10.001; CYP2D6.10.001,"3,4-methylenedioxymethamphetamine",de,0.5,"CYP2D6 *4/*4  is associated with decreased metabolism of 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.",CC(CC1=CC2=C(C=C1)OCO2)NC,CYP2D6 Intermediate Metabolizer
1448109032,PMCID:PMC4949007,CYP2D6.5.001; CYP2D6.10.001,"3,4-methylenedioxymethamphetamine",de,0.25,"CYP2D6 *4/*4  is associated with decreased metabolism of 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.",CC(CC1=CC2=C(C=C1)OCO2)NC,CYP2D6 Intermediate Metabolizer
1448109032,PMCID:PMC4949007,CYP2D6.2.001; CYP2D6.41.001,"3,4-methylenedioxymethamphetamine",nor,1.25,"CYP2D6 *4/*4  is associated with decreased metabolism of 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.",CC(CC1=CC2=C(C=C1)OCO2)NC,CYP2D6 Normal Metabolizer
1448109032,PMCID:PMC4949007,CYP2D6.10.001; CYP2D6.41.001,"3,4-methylenedioxymethamphetamine",de,0.5,"CYP2D6 *4/*4  is associated with decreased metabolism of 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.",CC(CC1=CC2=C(C=C1)OCO2)NC,CYP2D6 Intermediate Metabolizer
1448109032,PMCID:PMC4949007,CYP2D6.2.001; CYP2D6.5.001,"3,4-methylenedioxymethamphetamine",nor,1,"CYP2D6 *4/*4  is associated with decreased metabolism of 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.",CC(CC1=CC2=C(C=C1)OCO2)NC,CYP2D6 Intermediate Metabolizer
1448109032,PMCID:PMC4949007,CYP2D6.2.001; CYP2D6.4.001,"3,4-methylenedioxymethamphetamine",nor,1,"CYP2D6 *4/*4  is associated with decreased metabolism of 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.",CC(CC1=CC2=C(C=C1)OCO2)NC,CYP2D6 Intermediate Metabolizer
1446903345,PMID:16024198,CYP2D6.4.001; CYP2D6.4.001,amitriptyline,f,0,CYP2D6 *4/*4 are associated with decreased metabolism of amitriptyline as compared to CYP2D6 *9 + *10 + *1 + *2.,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Poor Metabolizer
1183617206,PMID:12172336,CYP2D6.5.001; CYP2D6.10.001,amitriptyline,de,0.25,CYP2D6 *5/*10 is associated with increased ratio of nortriptyline and its metabolite (NT/EHNT) when treated with amitriptyline in people with Mental Disorders as compared to CYP2D6 *1/*1 + *1/*2.,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Intermediate Metabolizer
1183617442,PMID:15590749,CYP2D6.2.001; CYP2D6.5.001,amitriptyline,de,,"CYP2D6 *2/*5 are associated with increased risk of Drug Toxicity when treated with amitriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.",CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,
1446903345,PMID:16024198,CYP2D6.4.001; CYP2D6.5.001,amitriptyline,f,0,CYP2D6 *4/*5 are associated with decreased metabolism of amitriptyline as compared to CYP2D6 *9 + *10 + *1 + *2.,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Poor Metabolizer
1183617442,PMID:15590749,CYP2D6.1.001; CYP2D6.1.001,amitriptyline,nor,2,"CYP2D6 *1/*4 are associated with increased risk of Drug Toxicity when treated with amitriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.",CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Normal Metabolizer
1183617442,PMID:15590749,CYP2D6.1.001; CYP2D6.10.001,amitriptyline,nor,1.25,"CYP2D6 *1/*4 are associated with increased risk of Drug Toxicity when treated with amitriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.",CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Normal Metabolizer
1183617442,PMID:15590749,CYP2D6.2.001; CYP2D6.4.001,amitriptyline,de,1,"CYP2D6 *2/*4 are associated with increased risk of Drug Toxicity when treated with amitriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.",CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Intermediate Metabolizer
1183617442,PMID:15590749,CYP2D6.2.001; CYP2D6.41.001,amitriptyline,nor,1.25,"CYP2D6 *1/*4 are associated with increased risk of Drug Toxicity when treated with amitriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.",CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Normal Metabolizer
1183617442,PMID:15590749,CYP2D6.1.001; CYP2D6.2.001,amitriptyline,nor,2,"CYP2D6 *1/*4 are associated with increased risk of Drug Toxicity when treated with amitriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.",CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Normal Metabolizer
1183617442,PMID:15590749,CYP2D6.1.001; CYP2D6.4.001,amitriptyline,de,1,"CYP2D6 *1/*4 are associated with increased risk of Drug Toxicity when treated with amitriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.",CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Intermediate Metabolizer
1183617206,PMID:12172336,CYP2D6.10.001; CYP2D6.10.001,amitriptyline,de,0.5,CYP2D6 *10/*10 is associated with increased ratio of nortriptyline and its metabolite (NT/EHNT) when treated with amitriptyline in people with Mental Disorders as compared to CYP2D6 *1/*1 + *1/*2.,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Intermediate Metabolizer
1183688948,PMID:20691935,CYP2D6.1.001; CYP2D6.1.001,atomoxetine,nor,2,CYP2D6 *5/*41 are associated with increased risk of Drug Toxicity when treated with atomoxetine in children with Attention Deficit Disorder with Hyperactivity.,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2,CYP2D6 Normal Metabolizer
1446896699,PMID:25919121,CYP2D6.4.001; CYP2D6.5.001,atomoxetine,f,0,"CYP2D6 *4/*5 (assigned as poor metabolizers phenotype) are associated with increased risk of dry mouth, Erectile Dysfunction, Hyperhidrosis, insomnia and Urinary Retention when treated with atomoxetine in people with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*7 + *1/*1xN + *1/*1 + *1/*10 + *1/*17 + *3/*10 + *4/*10 + *4/*17 + *5/*10 + *5/*17 + *6/*10 + *10/*10 + *10/*17 + *17/*17.",CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2,CYP2D6 Poor Metabolizer
1183688948,PMID:20691935,CYP2D6.2.001; CYP2D6.2.001,atomoxetine,nor,2,CYP2D6 *5/*41 are associated with increased risk of Drug Toxicity when treated with atomoxetine in children with Attention Deficit Disorder with Hyperactivity.,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2,CYP2D6 Normal Metabolizer
1446896699,PMID:25919121,CYP2D6.5.001; CYP2D6.5.001,atomoxetine,f,0,"CYP2D6 *5/*5 (assigned as poor metabolizers phenotype) are associated with increased risk of dry mouth, Erectile Dysfunction, Hyperhidrosis, insomnia and Urinary Retention when treated with atomoxetine in people with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*7 + *1/*1xN + *1/*1 + *1/*10 + *1/*17 + *3/*10 + *4/*10 + *4/*17 + *5/*10 + *5/*17 + *6/*10 + *10/*10 + *10/*17 + *17/*17.",CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2,CYP2D6 Poor Metabolizer
1446896699,PMID:25919121,CYP2D6.3.001; CYP2D6.3.001,atomoxetine,f,0,"CYP2D6 *3/*3 (assigned as poor metabolizers phenotype) are associated with increased risk of dry mouth, Erectile Dysfunction, Hyperhidrosis, insomnia and Urinary Retention when treated with atomoxetine in people with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*7 + *1/*1xN + *1/*1 + *1/*10 + *1/*17 + *3/*10 + *4/*10 + *4/*17 + *5/*10 + *5/*17 + *6/*10 + *10/*10 + *10/*17 + *17/*17.",CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2,CYP2D6 Poor Metabolizer
1446896699,PMID:25919121,CYP2D6.4.001; CYP2D6.6.001,atomoxetine,f,0,"CYP2D6 *4/*6 (assigned as poor metabolizers phenotype) are associated with increased risk of dry mouth, Erectile Dysfunction, Hyperhidrosis, insomnia and Urinary Retention when treated with atomoxetine in people with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*7 + *1/*1xN + *1/*1 + *1/*10 + *1/*17 + *3/*10 + *4/*10 + *4/*17 + *5/*10 + *5/*17 + *6/*10 + *10/*10 + *10/*17 + *17/*17.",CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2,CYP2D6 Poor Metabolizer
1183688948,PMID:20691935,CYP2D6.1.001; CYP2D6.9.001,atomoxetine,de,1.25,CYP2D6 *5/*41 are associated with increased risk of Drug Toxicity when treated with atomoxetine in children with Attention Deficit Disorder with Hyperactivity.,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2,CYP2D6 Normal Metabolizer
1447814409,PMID:26254792,CYP2D6.10.001; CYP2D6.10.001,atomoxetine,de,0.5,CYP2D6 *10/*10 are associated with increased concentrations of atomoxetine in healthy individuals as compared to CYP2D6 *1/*1.,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2,CYP2D6 Intermediate Metabolizer
1446896699,PMID:25919121,CYP2D6.3.001; CYP2D6.4.001,atomoxetine,f,0,"CYP2D6 *3/*4 (assigned as poor metabolizers phenotype) are associated with increased risk of dry mouth, Erectile Dysfunction, Hyperhidrosis, insomnia and Urinary Retention when treated with atomoxetine in people with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*7 + *1/*1xN + *1/*1 + *1/*10 + *1/*17 + *3/*10 + *4/*10 + *4/*17 + *5/*10 + *5/*17 + *6/*10 + *10/*10 + *10/*17 + *17/*17.",CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2,CYP2D6 Poor Metabolizer
1446896699,PMID:25919121,CYP2D6.3.001; CYP2D6.6.001,atomoxetine,f,0,"CYP2D6 *3/*6 (assigned as poor metabolizers phenotype) are associated with increased risk of dry mouth, Erectile Dysfunction, Hyperhidrosis, insomnia and Urinary Retention when treated with atomoxetine in people with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*7 + *1/*1xN + *1/*1 + *1/*10 + *1/*17 + *3/*10 + *4/*10 + *4/*17 + *5/*10 + *5/*17 + *6/*10 + *10/*10 + *10/*17 + *17/*17.",CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2,CYP2D6 Poor Metabolizer
1183688957,PMID:20691935,CYP2D6.2.001; CYP2D6.4.001,atomoxetine,de,1,CYP2D6 *2/*4 is associated with dose reduction to increase tolerability when treated with atomoxetine in children with Attention Deficit Disorder with Hyperactivity.,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2,CYP2D6 Intermediate Metabolizer
982044314,PMID:17329852,CYP2D6.1.001; CYP2D6.4.001,carvedilol,de,1,CYP2D6 *1/*4 is associated with decreased clearance of carvedilol in people with Heart Diseases as compared to CYP2D6 *1/*1.,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O,CYP2D6 Intermediate Metabolizer
827807123,PMID:21599570,CYP2D6.5.001; CYP2D6.5.001,carvedilol,f,0,CYP2D6 *5/*5 is associated with decreased clearance of carvedilol in healthy individuals as compared to CYP2D6 *1/*1.,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O,CYP2D6 Poor Metabolizer
982044321,PMID:17329852,CYP2D6.1.001; CYP2D6.5.001,carvedilol,de,1,CYP2D6 *1/*5 is associated with decreased clearance of carvedilol in people with Heart Diseases as compared to CYP2D6 *1/*1.,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O,CYP2D6 Intermediate Metabolizer
827807126,PMID:21599570,CYP2D6.6.001; CYP2D6.6.001,carvedilol,f,0,CYP2D6 *6/*6 is associated with decreased clearance of carvedilol in healthy individuals as compared to CYP2D6 *1/*1.,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O,CYP2D6 Poor Metabolizer
982044327,PMID:17329852,CYP2D6.10.001; CYP2D6.10.001,carvedilol,de,0.5,CYP2D6 *10/*10 is associated with decreased clearance of carvedilol in people with Heart Diseases as compared to CYP2D6 *1/*1.,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O,CYP2D6 Intermediate Metabolizer
827807118,PMID:21599570,CYP2D6.4.001; CYP2D6.4.001,carvedilol,f,0,CYP2D6 *4/*4 is associated with increased clearance of carvedilol in healthy individuals as compared to CYP2D6 *1/*1.,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O,CYP2D6 Poor Metabolizer
1183617434,PMCID:PMC2291379,CYP2D6.4.001; CYP2D6.4.001,citalopram,f,0,"CYP2D6 *4/*4 is associated with decreased dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline in people with Depression as compared to CYP2D6 *1/*1.",CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CYP2D6 Poor Metabolizer
1183701546,PMID:23981149,CYP2D6.1.001; CYP2D6.1.001,citalopram,nor,2,CYP2D6 *1/*10 is associated with decreased clearance of citalopram in healthy individuals as compared to CYP2D6 *1/*1.,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CYP2D6 Normal Metabolizer
1183701546,PMID:23981149,CYP2D6.1.001; CYP2D6.10.001,citalopram,de,1.25,CYP2D6 *1/*10 is associated with decreased clearance of citalopram in healthy individuals as compared to CYP2D6 *1/*1.,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CYP2D6 Normal Metabolizer
1183847020,PMID:19840783,CYP2D6.1.001; CYP2D6.4.001,citalopram,de,1,CYP2D6 *1/*4 is associated with increased AUC of citalopram when treated with citalopram in healthy individuals as compared to CYP2D6 *1/*1.,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CYP2D6 Intermediate Metabolizer
1183617426,PMCID:PMC2291379,CYP2D6.1.001; CYP2D6.1.001,clomipramine,nor,2,"CYP2D6 *4/*4 is associated with decreased dose of amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.",CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,CYP2D6 Normal Metabolizer
1183617426,PMCID:PMC2291379,CYP2D6.4.001; CYP2D6.4.001,clomipramine,f,0,"CYP2D6 *4/*4 is associated with decreased dose of amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.",CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,CYP2D6 Poor Metabolizer
1183616898,PMID:8181196,CYP2D6.4.001; CYP2D6.5.001,clomipramine,f,0,CYP2D6 *4/*5 (assigned as poor metabolizers phenotype) is associated with decreased clearance of clomipramine in healthy individuals as compared to CYP2D6 *1 (assigned as normal metabolizers phenotype) .,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,CYP2D6 Poor Metabolizer
1448631815,PMID:28470111,CYP2D6.4.001; CYP2D6.41.001,clomipramine,de,0.25,CYP2D6 *4/*41 is associated with increased trough concentration of clomipramine and desmethyl clomipramine.,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,CYP2D6 Intermediate Metabolizer
1183616907,PMID:8181196,CYP2D6.3.001; CYP2D6.4.001,clomipramine,f,0,CYP2D6 *3/*4 (assigned as poor metabolizers phenotype) is associated with decreased clearance of clomipramine in healthy individuals as compared to CYP2D6 *1 (assigned as normal metabolizers phenotype) .,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,CYP2D6 Poor Metabolizer
1452151189,PMID:18346175,CYP2D6.4.001; CYP2D6.6.001,clozapine,f,0,"CYP2D6 *4/*6 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CYP2D6 Poor Metabolizer
1452151189,PMID:18346175,CYP2D6.4.001; CYP2D6.5.001,clozapine,f,0,"CYP2D6 *4/*5 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CYP2D6 Poor Metabolizer
1452151321,PMID:18346175,CYP2D6.1.001; CYP2D6.1.001,clozapine,nor,2,"CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CYP2D6 Normal Metabolizer
1452151189,PMID:18346175,CYP2D6.3.001; CYP2D6.4.001,clozapine,f,0,"CYP2D6 *3/*4 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CYP2D6 Poor Metabolizer
1183680624,PMID:19395173,CYP2D6.1.001; CYP2D6.1.001,codeine,nor,2,CYP2D6 *1/*1 is associated with increased metabolism of codeine in healthy individuals.,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O,CYP2D6 Normal Metabolizer
1184756913,PMID:11823760,CYP2D6.5.001; CYP2D6.17.001,codeine,de,0.5,"CYP2D6 *5/*17 is associated with decreased metabolism of codeine, debrisoquine, dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *17/*17 + *1/*1.",CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O,CYP2D6 Intermediate Metabolizer
1184756952,PMID:11823760,CYP2D6.29.001; CYP2D6.29.001,codeine,de,1,CYP2D6 *29/*29 is associated with decreased metabolism of codeine or debrisoquine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O,CYP2D6 Intermediate Metabolizer
1183680972,PMID:9129563,CYP2D6.5.001; CYP2D6.5.001,codeine,f,0,CYP2D6 *5/*5 is not associated with oroceccal transit time when treated with codeine in healthy individuals.,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O,CYP2D6 Poor Metabolizer
1183680612,PMID:19395173,CYP2D6.4.001; CYP2D6.6.001,codeine,f,0,CYP2D6 *4/*6 is associated with decreased metabolism of codeine in healthy individuals.,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O,CYP2D6 Poor Metabolizer
1183632376,PMID:21743374,CYP2D6.4.001; CYP2D6.5.001,codeine,de,0,CYP2D6 *4/*5 is associated with decreased analgesia from codeine for postpartum pain management when treated with codeine in women as compared to CYP2D6 *1/*1.,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O,CYP2D6 Poor Metabolizer
1183680618,PMID:19395173,CYP2D6.4.001; CYP2D6.41.001,codeine,de,0.25,CYP2D6 *4/*41 is associated with decreased metabolism of codeine in healthy individuals.,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O,CYP2D6 Intermediate Metabolizer
1183632349,PMID:24077935,CYP2D6.1.001; CYP2D6.10.001,codeine,de,1.25,"CYP2D6 *1/*10 is associated with decreased plasma levels of morphine, M3G and M6G levels but not those of codeine when treated with codeine in healthy individuals as compared to CYP2D6 *1/*1.",CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O,CYP2D6 Normal Metabolizer
1183632366,PMID:19940985,CYP2D6.1.001; CYP2D6.4.001,codeine,nor,1,"CYP2D6 *4/*4 is associated with decreased metabolism of codeine in people with Kidney Failure, Chronic as compared to CYP2D6 *1/*1 + *1/*4.",CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O,CYP2D6 Intermediate Metabolizer
1183680972,PMID:9129563,CYP2D6.3.001; CYP2D6.4.001,codeine,f,0,CYP2D6 *3/*4 is not associated with oroceccal transit time when treated with codeine in healthy individuals.,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O,CYP2D6 Poor Metabolizer
1183629572,PMCID:PMC2751283,CYP2D6.3.001; CYP2D6.4.001,debrisoquine,f,0,CYP2D6 *3/*4 is associated with metabolism of debrisoquine or dextromethorphan.,C1CN(CC2=CC=CC=C21)C(=N)N,CYP2D6 Poor Metabolizer
1447990816,PMCID:PMC2042718,CYP2D6.1.001; CYP2D6.17.001,debrisoquine,de,1.5,CYP2D6 *1/*17 is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.,C1CN(CC2=CC=CC=C21)C(=N)N,CYP2D6 Normal Metabolizer
1184756755,PMID:9918137,CYP2D6.4.001; CYP2D6.38.001,debrisoquine,f,0,CYP2D6 *4/*38 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of debrisoquine.,C1CN(CC2=CC=CC=C21)C(=N)N,CYP2D6 Poor Metabolizer
1184755450,PMID:8530011,CYP2D6.5.001; CYP2D6.8.001,debrisoquine,f,0,CYP2D6 *5/*8 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of debrisoquine or sparteine in healthy individuals.,C1CN(CC2=CC=CC=C21)C(=N)N,CYP2D6 Poor Metabolizer
1183629554,PMCID:PMC2751283,CYP2D6.3.001; CYP2D6.5.001,debrisoquine,f,0,CYP2D6 *3/*5 is associated with decreased metabolism of debrisoquine or dextromethorphan.,C1CN(CC2=CC=CC=C21)C(=N)N,CYP2D6 Poor Metabolizer
1184756913,PMID:11823760,CYP2D6.5.001; CYP2D6.17.001,debrisoquine,de,0.5,"CYP2D6 *5/*17 is associated with decreased metabolism of codeine, debrisoquine, dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *17/*17 + *1/*1.",C1CN(CC2=CC=CC=C21)C(=N)N,CYP2D6 Intermediate Metabolizer
1184756952,PMID:11823760,CYP2D6.29.001; CYP2D6.29.001,debrisoquine,de,1,CYP2D6 *29/*29 is associated with decreased metabolism of codeine or debrisoquine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.,C1CN(CC2=CC=CC=C21)C(=N)N,CYP2D6 Intermediate Metabolizer
1184756733,PMID:9918137,CYP2D6.4.001; CYP2D6.17.001,debrisoquine,de,0.5,CYP2D6 *4/*17 is associated with decreased metabolism of debrisoquine.,C1CN(CC2=CC=CC=C21)C(=N)N,CYP2D6 Intermediate Metabolizer
1446899532,PMID:26211952,CYP2D6.4.001; CYP2D6.4.001,debrisoquine,f,0,CYP2D6 *4/*4 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*1.,C1CN(CC2=CC=CC=C21)C(=N)N,CYP2D6 Poor Metabolizer
1447990805,PMCID:PMC2042718,CYP2D6.1.001; CYP2D6.2.001,debrisoquine,nor,2,CYP2D6 *1/*2 is not associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*1.,C1CN(CC2=CC=CC=C21)C(=N)N,CYP2D6 Normal Metabolizer
1447990710,PMID:10022755,CYP2D6.4.001; CYP2D6.5.001,debrisoquine,f,0,CYP2D6 *4/*5 are associated with decreased metabolism of debrisoquine in healthy individuals.,C1CN(CC2=CC=CC=C21)C(=N)N,CYP2D6 Poor Metabolizer
1184756094,PMID:8807669,CYP2D6.4.001; CYP2D6.15.001,debrisoquine,f,0,CYP2D6 *4/*15 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of debrisoquine or dextromethorphan in healthy individuals.,C1CN(CC2=CC=CC=C21)C(=N)N,CYP2D6 Poor Metabolizer
1447991368,PMID:7935325,CYP2D6.10.001; CYP2D6.10.001,debrisoquine,de,0.5,CYP2D6 *10/*10 is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*1.,C1CN(CC2=CC=CC=C21)C(=N)N,CYP2D6 Intermediate Metabolizer
1447990710,PMID:10022755,CYP2D6.3.001; CYP2D6.3.001,debrisoquine,f,0,CYP2D6 *3/*3 are associated with decreased metabolism of debrisoquine in healthy individuals.,C1CN(CC2=CC=CC=C21)C(=N)N,CYP2D6 Poor Metabolizer
1184756965,PMID:11823760,CYP2D6.17.001; CYP2D6.17.001,debrisoquine,de,1,CYP2D6 *17/*17 is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *29/*29.,C1CN(CC2=CC=CC=C21)C(=N)N,CYP2D6 Intermediate Metabolizer
1184756952,PMID:11823760,CYP2D6.1.001; CYP2D6.1.001,debrisoquine,nor,2,CYP2D6 *29/*29 is associated with decreased metabolism of codeine or debrisoquine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.,C1CN(CC2=CC=CC=C21)C(=N)N,CYP2D6 Normal Metabolizer
1183621960,PMID:10895986,CYP2D6.5.001; CYP2D6.10.001,desipramine,de,0.25,CYP2D6 *5/*10 is associated with increased desipramine/2-hydroxy-desipramine ratio when treated with desipramine in people with Mental Disorders as compared to CYP2D6 *1/*1 + *1/*2.,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Intermediate Metabolizer
1183622026,PMID:15115913,CYP2D6.1.001; CYP2D6.4.001,desipramine,de,1,CYP2D6 *1/*4 is associated with increased desipramine elimination half-life and total exposure when exposed to desipramine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Intermediate Metabolizer
1446902165,PMID:17667959,CYP2D6.4.001; CYP2D6.4.001,desipramine,f,0,"CYP2D6 *4/*4 (assigned as poor metabolizers phenotype) is associated with increased concentrations of desipramine and imipramine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.",CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Poor Metabolizer
1183622026,PMID:15115913,CYP2D6.1.001; CYP2D6.1.001,desipramine,nor,2,CYP2D6 *1/*4 is associated with increased desipramine elimination half-life and total exposure when exposed to desipramine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Normal Metabolizer
1446902165,PMID:17667959,CYP2D6.4.001; CYP2D6.5.001,desipramine,f,0,"CYP2D6 *4/*5 (assigned as poor metabolizers phenotype) is associated with increased concentrations of desipramine and imipramine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.",CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Poor Metabolizer
1183621960,PMID:10895986,CYP2D6.10.001; CYP2D6.10.001,desipramine,de,0.5,CYP2D6 *10/*10 is associated with increased desipramine/2-hydroxy-desipramine ratio when treated with desipramine in people with Mental Disorders as compared to CYP2D6 *1/*1 + *1/*2.,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Intermediate Metabolizer
1451664485,PMID:32365274,CYP2D6.1.001; CYP2D6.1.001,desvenlafaxine,nor,2,CYP2D6 *4/*4 is associated with decreased concentrations of desvenlafaxine in women with Depressive Disorder.,CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,CYP2D6 Poor Metabolizer
1446899262,PMCID:PMC4630174,CYP2D6.4.001; CYP2D6.59.001,dextromethorphan,de,0.5,CYP2D6 *4/*59 (assigned as intermediate metabolizers phenotype) is associated with decreased metabolism of dextromethorphan.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,CYP2D6 Intermediate Metabolizer
1184756523,PMID:15618746,CYP2D6.10.001; CYP2D6.21.001,dextromethorphan,de,0.25,CYP2D6 *10/*21 are associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*2.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,CYP2D6 Intermediate Metabolizer
1183623913,PMID:18359183,CYP2D6.4.001; CYP2D6.4.001,dextromethorphan,f,0,CYP2D6 *4/*4 is associated with Poisoning when treated with amitriptyline and dextromethorphan.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,CYP2D6 Poor Metabolizer
1184756664,PMID:10340923,CYP2D6.5.001; CYP2D6.5.001,dextromethorphan,f,0,CYP2D6 *5/*5 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,CYP2D6 Poor Metabolizer
1446899270,PMCID:PMC4630174,CYP2D6.2.001; CYP2D6.59.001,dextromethorphan,nor,1.5,CYP2D6 *2/*59 (assigned as normal metabolizers phenotype) is not associated with decreased metabolism of dextromethorphan.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,CYP2D6 Normal Metabolizer
1184819093,PMID:18797858,CYP2D6.4.001; CYP2D6.69.001,dextromethorphan,f,0,CYP2D6 *4/*69 is associated with decreased metabolism of dextromethorphan in healthy individuals.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,CYP2D6 Poor Metabolizer
1449157575,PMID:19364831,CYP2D6.49.001; CYP2D6.52.001,dextromethorphan,de,0.75,CYP2D6 *49/*52 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,CYP2D6 Intermediate Metabolizer
1184756913,PMID:11823760,CYP2D6.1.001; CYP2D6.1.001,dextromethorphan,nor,2,"CYP2D6 *5/*17 is associated with decreased metabolism of codeine, debrisoquine, dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *17/*17 + *1/*1.",CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,CYP2D6 Normal Metabolizer
1184757079,PMID:12152006,CYP2D6.6.001; CYP2D6.40.001,dextromethorphan,f,0,CYP2D6 *6/*40 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan in healthy individuals.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,CYP2D6 Poor Metabolizer
1183629548,PMCID:PMC2751283,CYP2D6.4.001; CYP2D6.5.001,dextromethorphan,f,0,CYP2D6 *4/*5 is associated with decreased metabolism of debrisoquine or dextromethorphan.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,CYP2D6 Poor Metabolizer
1446897132,PMID:16415111,CYP2D6.4.001; CYP2D6.36.001,dextromethorphan,f,0,CYP2D6 *4/*36 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,CYP2D6 Poor Metabolizer
1449157575,PMID:19364831,CYP2D6.10.001; CYP2D6.52.001,dextromethorphan,de,0.5,CYP2D6 *10/*52 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,CYP2D6 Intermediate Metabolizer
1184756902,PMID:11823760,CYP2D6.17.001; CYP2D6.17.001,dextromethorphan,de,1,"CYP2D6 *17/*17 is associated with decreased metabolism of debrisoquine, dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.",CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,CYP2D6 Intermediate Metabolizer
1448617711,PMCID:PMC5411458,CYP2D6.5.001; CYP2D6.10.001,dextromethorphan,de,0.25,CYP2D6 *5/*10 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10 + *10/*10.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,CYP2D6 Intermediate Metabolizer
1184756941,PMID:11823760,CYP2D6.29.001; CYP2D6.29.001,dextromethorphan,de,1,CYP2D6 *29/*29 is associated with decreased metabolism of dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,CYP2D6 Intermediate Metabolizer
1184757143,PMID:12811367,CYP2D6.40.001; CYP2D6.42.001,dextromethorphan,f,0,CYP2D6 *40/*42 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan in healthy individuals.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,CYP2D6 Poor Metabolizer
1184763881,PMID:19158312,CYP2D6.10.001; CYP2D6.10.001,dextromethorphan,de,0.5,CYP2D6 *10/*10 is associated with decreased enzyme activity of CYP2D6 when assayed with dextromethorphan in liver microsomes as compared to CYP2D6 *1/*1.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,CYP2D6 Intermediate Metabolizer
1448110342,PMID:27339126,CYP2D6.1.001; CYP2D6.10.001,dextromethorphan,nor,1.25,CYP2D6 *10/*10 is associated with decreased clearance of dextromethorphan as compared to CYP2D6 *1/*1.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,CYP2D6 Normal Metabolizer
1183629554,PMCID:PMC2751283,CYP2D6.3.001; CYP2D6.5.001,dextromethorphan,f,0,CYP2D6 *3/*5 is associated with decreased metabolism of debrisoquine or dextromethorphan.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,CYP2D6 Poor Metabolizer
1449157587,PMID:19364831,CYP2D6.10.001; CYP2D6.49.001,dextromethorphan,de,0.75,CYP2D6 *10/*49 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*10.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,CYP2D6 Intermediate Metabolizer
1184756094,PMID:8807669,CYP2D6.4.001; CYP2D6.15.001,dextromethorphan,f,0,CYP2D6 *4/*15 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of debrisoquine or dextromethorphan in healthy individuals.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,CYP2D6 Poor Metabolizer
1184989053,PMID:23394389,CYP2D6.5.001; CYP2D6.100.001,dextromethorphan,f,0,CYP2D6 *5/*100 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan in healthy individuals.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,CYP2D6 Poor Metabolizer
1183629572,PMCID:PMC2751283,CYP2D6.3.001; CYP2D6.4.001,dextromethorphan,f,0,CYP2D6 *3/*4 is associated with metabolism of debrisoquine or dextromethorphan.,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,CYP2D6 Poor Metabolizer
1451152920,PMCID:PMC2042888,CYP2D6.4.001; CYP2D6.4.001,dihydrocodeine,f,0,CYP2D6 *4/*4 is associated with decreased metabolism of dihydrocodeine as compared to CYP2D6 *1/*1 + *1/*4.,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](CC4)O,CYP2D6 Poor Metabolizer
1451152920,PMCID:PMC2042888,CYP2D6.1.001; CYP2D6.4.001,dihydrocodeine,nor,1,CYP2D6 *4/*4 is associated with decreased metabolism of dihydrocodeine as compared to CYP2D6 *1/*1 + *1/*4.,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](CC4)O,CYP2D6 Intermediate Metabolizer
1184511101,PMCID:PMC4168388,CYP2D6.1.001; CYP2D6.1.001,donepezil,nor,2,CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with increased likelihood of adverse events when treated with donepezil in people with Alzheimer Disease.,COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC,CYP2D6 Poor Metabolizer
1184511101,PMCID:PMC4168388,CYP2D6.4.001; CYP2D6.5.001,donepezil,f,0,CYP2D6 *4/*5 (assigned as poor metabolizer phenotype) is associated with increased likelihood of adverse events when treated with donepezil in people with Alzheimer Disease.,COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC,CYP2D6 Poor Metabolizer
1446905879,PMID:12360109,CYP2D6.4.001; CYP2D6.5.001,doxepin,f,0,CYP2D6 *4/*5 are associated with decreased metabolism of doxepin in healthy individuals as compared to CYP2D6 *1/*1.,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CYP2D6 Poor Metabolizer
1446905879,PMID:12360109,CYP2D6.3.001; CYP2D6.5.001,doxepin,f,0,CYP2D6 *3/*5 are associated with decreased metabolism of doxepin in healthy individuals as compared to CYP2D6 *1/*1.,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CYP2D6 Poor Metabolizer
1184348901,PMID:22999230,CYP2D6.1.001; CYP2D6.41.001,doxepin,de,1.25,CYP2D6 *1/*41 is associated with doxepin intoxication when treated with doxepin.,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CYP2D6 Normal Metabolizer
1446905682,PMID:17721180,CYP2D6.3.001; CYP2D6.4.001,doxepin,f,0,CYP2D6 *3/*4 is associated with decreased metabolism of doxepin.,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CYP2D6 Poor Metabolizer
1451664500,PMID:32365274,CYP2D6.4.001; CYP2D6.4.001,duloxetine,f,0,CYP2D6 *4/*4 is associated with increased concentrations of duloxetine in women with Depressive Disorder.,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CYP2D6 Poor Metabolizer
1183617434,PMCID:PMC2291379,CYP2D6.4.001; CYP2D6.4.001,escitalopram,f,0,"CYP2D6 *4/*4 is associated with decreased dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline in people with Depression as compared to CYP2D6 *1/*1.",CN(C)CCC[C@@]1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CYP2D6 Poor Metabolizer
1183617434,PMCID:PMC2291379,CYP2D6.1.001; CYP2D6.1.001,escitalopram,nor,2,"CYP2D6 *4/*4 is associated with decreased dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline in people with Depression as compared to CYP2D6 *1/*1.",CN(C)CCC[C@@]1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CYP2D6 Normal Metabolizer
1451152700,PMCID:PMC1364985,CYP2D6.1.001; CYP2D6.4.001,ethylmorphine,nor,1,CYP2D6 *4/*4 is associated with decreased enzyme activity of CYP2D6 when assayed with ethylmorphine as compared to CYP2D6 *1/*1 + *1/*4.,CCOC1=C2C3=C(C[C@@H]4[C@H]5[C@]3(CCN4C)[C@@H](O2)[C@H](C=C5)O)C=C1,CYP2D6 Intermediate Metabolizer
1451152700,PMCID:PMC1364985,CYP2D6.4.001; CYP2D6.4.001,ethylmorphine,f,0,CYP2D6 *4/*4 is associated with decreased enzyme activity of CYP2D6 when assayed with ethylmorphine as compared to CYP2D6 *1/*1 + *1/*4.,CCOC1=C2C3=C(C[C@@H]4[C@H]5[C@]3(CCN4C)[C@@H](O2)[C@H](C=C5)O)C=C1,CYP2D6 Poor Metabolizer
1451208192,PMID:25825958,CYP2D6.10.001; CYP2D6.10.001,fentanyl,de,0.5,"CYP2D6 *10/*10 is associated with increased dose of fentanyl in people with Gastrointestinal Neoplasms and Pain, Postoperative as compared to CYP2D6 *1/*1.",CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CYP2D6 Intermediate Metabolizer
1183621673,PMID:16944116,CYP2D6.1.001; CYP2D6.2.001,flecainide,nor,2,CYP2D6 *5/*36 are associated with decreased oral clearance (CL/F) of flecainide in patients with supraventricular tachyarrhythmia when treated with flecainide as compared to CYP2D6 *1/*1 + *1/*2.,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,CYP2D6 Normal Metabolizer
1183621673,PMID:16944116,CYP2D6.21.001; CYP2D6.36.001,flecainide,de,0,CYP2D6 *21/*36 are associated with decreased oral clearance (CL/F) of flecainide in patients with supraventricular tachyarrhythmia when treated with flecainide as compared to CYP2D6 *1/*1 + *1/*2.,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,CYP2D6 Poor Metabolizer
1183621673,PMID:16944116,CYP2D6.10.001; CYP2D6.10.001,flecainide,de,0.5,CYP2D6 *10/*10 are associated with decreased oral clearance (CL/F) of flecainide in patients with supraventricular tachyarrhythmia when treated with flecainide as compared to CYP2D6 *1/*1 + *1/*2.,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,CYP2D6 Intermediate Metabolizer
1183621673,PMID:16944116,CYP2D6.5.001; CYP2D6.36.001,flecainide,de,0,CYP2D6 *5/*36 are associated with decreased oral clearance (CL/F) of flecainide in patients with supraventricular tachyarrhythmia when treated with flecainide as compared to CYP2D6 *1/*1 + *1/*2.,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,CYP2D6 Poor Metabolizer
1183621673,PMID:16944116,CYP2D6.1.001; CYP2D6.1.001,flecainide,nor,2,CYP2D6 *5/*36 are associated with decreased oral clearance (CL/F) of flecainide in patients with supraventricular tachyarrhythmia when treated with flecainide as compared to CYP2D6 *1/*1 + *1/*2.,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,CYP2D6 Normal Metabolizer
1449577638,PMID:20118554,CYP2D6.10.001; CYP2D6.14.001,fluvoxamine,de,0.75,CYP2D6 *10/*14 are associated with increased steady-state concentration of fluvoxamine as compared to CYP2D6 *1/*1.,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,CYP2D6 Intermediate Metabolizer
1184137435,PMID:18978520,CYP2D6.5.001; CYP2D6.10.001,fluvoxamine,de,0.25,CYP2D6 *5/*10 are associated with differences in the fluvoxamine plasma level at 50 mg/day when treated with fluvoxamine in people with as compared to CYP2D6 *1/*1.,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,CYP2D6 Intermediate Metabolizer
1184137435,PMID:18978520,CYP2D6.1.001; CYP2D6.1.001,fluvoxamine,nor,2,CYP2D6 *1/*10 are associated with differences in the fluvoxamine plasma level at 50 mg/day when treated with fluvoxamine in people with as compared to CYP2D6 *1/*1.,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,CYP2D6 Normal Metabolizer
1183703493,PMID:10668847,CYP2D6.4.001; CYP2D6.6.001,fluvoxamine,f,0,"CYP2D6 *4/*6 (assigned as poor metabolizer phenotype) is associated with increased AUC, Cmax and half-life time of fluvoxamine when treated with fluvoxamine in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,CYP2D6 Poor Metabolizer
1184137435,PMID:18978520,CYP2D6.10.001; CYP2D6.10.001,fluvoxamine,de,0.5,CYP2D6 *10/*10 are associated with differences in the fluvoxamine plasma level at 50 mg/day when treated with fluvoxamine in people with as compared to CYP2D6 *1/*1.,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,CYP2D6 Intermediate Metabolizer
1184135944,PMID:23503455,CYP2D6.6.001; CYP2D6.41.001,galantamine,de,0.25,CYP2D6 *6/*41 (assigned as heterozygous normal metabolizer phenotype) are not associated with dose-adjusted plasma levels of galantamine in people with Dementia as compared to CYP2D6 *1/*1 + *1/*41 + *4/*1xN (assigned as normal metabolizers phenotype) .,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O,CYP2D6 Intermediate Metabolizer
1184135944,PMID:23503455,CYP2D6.1.001; CYP2D6.4.001,galantamine,de,1,CYP2D6 *1/*4 (assigned as heterozygous normal metabolizer phenotype) are not associated with dose-adjusted plasma levels of galantamine in people with Dementia as compared to CYP2D6 *1/*1 + *1/*41 + *4/*1xN (assigned as normal metabolizers phenotype) .,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O,CYP2D6 Intermediate Metabolizer
1184135944,PMID:23503455,CYP2D6.4.001; CYP2D6.41.001,galantamine,de,0.25,CYP2D6 *4/*41 (assigned as heterozygous normal metabolizer phenotype) are not associated with dose-adjusted plasma levels of galantamine in people with Dementia as compared to CYP2D6 *1/*1 + *1/*41 + *4/*1xN (assigned as normal metabolizers phenotype) .,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O,CYP2D6 Intermediate Metabolizer
1184135927,PMID:23503455,CYP2D6.3.001; CYP2D6.4.001,galantamine,f,0,CYP2D6 *3/*4 (assigned as poor metabolizers phenotype) are associated with increased dose-adjusted plasma levels of galantamine in people with Dementia as compared to CYP2D6 *1/*1 + *1/*41 + *4/*1xN (assigned as normal metabolizers phenotype) .,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O,CYP2D6 Poor Metabolizer
1184135927,PMID:23503455,CYP2D6.1.001; CYP2D6.41.001,galantamine,nor,1.25,CYP2D6 *3/*4 (assigned as poor metabolizers phenotype) are associated with increased dose-adjusted plasma levels of galantamine in people with Dementia as compared to CYP2D6 *1/*1 + *1/*41 + *4/*1xN (assigned as normal metabolizers phenotype) .,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O,CYP2D6 Normal Metabolizer
1184135927,PMID:23503455,CYP2D6.4.001; CYP2D6.4.001,galantamine,f,0,CYP2D6 *4/*4 (assigned as poor metabolizers phenotype) are associated with increased dose-adjusted plasma levels of galantamine in people with Dementia as compared to CYP2D6 *1/*1 + *1/*41 + *4/*1xN (assigned as normal metabolizers phenotype) .,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O,CYP2D6 Poor Metabolizer
1447948592,PMID:16719544,CYP2D6.2.001; CYP2D6.41.001,gefitinib,nor,1.25,CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with increased concentrations of gefitinib in healthy individuals as compared to CYP2D6 *1/*4 + *1/*2 + *2/*4 + *1/*3 + *2/*5 + *2/*41 (assigned as normal metabolizer phenotype) .,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,CYP2D6 Normal Metabolizer
1447948592,PMID:16719544,CYP2D6.1.001; CYP2D6.2.001,gefitinib,nor,2,CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with increased concentrations of gefitinib in healthy individuals as compared to CYP2D6 *1/*4 + *1/*2 + *2/*4 + *1/*3 + *2/*5 + *2/*41 (assigned as normal metabolizer phenotype) .,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,CYP2D6 Normal Metabolizer
1447948592,PMID:16719544,CYP2D6.4.001; CYP2D6.5.001,gefitinib,f,0,CYP2D6 *4/*5 (assigned as poor metabolizer phenotype) is associated with increased concentrations of gefitinib in healthy individuals as compared to CYP2D6 *1/*4 + *1/*2 + *2/*4 + *1/*3 + *2/*5 + *2/*41 (assigned as normal metabolizer phenotype) .,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,CYP2D6 Poor Metabolizer
1447948592,PMID:16719544,CYP2D6.4.001; CYP2D6.6.001,gefitinib,f,0,CYP2D6 *4/*6 (assigned as poor metabolizer phenotype) is associated with increased concentrations of gefitinib in healthy individuals as compared to CYP2D6 *1/*4 + *1/*2 + *2/*4 + *1/*3 + *2/*5 + *2/*41 (assigned as normal metabolizer phenotype) .,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,CYP2D6 Poor Metabolizer
1447948494,PMID:21502555,CYP2D6.1.001; CYP2D6.5.001,gefitinib,de,1,CYP2D6 *1/*5 is associated with Toxic liver disease when treated with gefitinib in people with Adenocarcinoma.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,CYP2D6 Intermediate Metabolizer
1447948592,PMID:16719544,CYP2D6.3.001; CYP2D6.4.001,gefitinib,f,0,CYP2D6 *3/*4 (assigned as poor metabolizer phenotype) is associated with increased concentrations of gefitinib in healthy individuals as compared to CYP2D6 *1/*4 + *1/*2 + *2/*4 + *1/*3 + *2/*5 + *2/*41 (assigned as normal metabolizer phenotype) .,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,CYP2D6 Poor Metabolizer
1447948592,PMID:16719544,CYP2D6.2.001; CYP2D6.4.001,gefitinib,nor,1,CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with increased concentrations of gefitinib in healthy individuals as compared to CYP2D6 *1/*4 + *1/*2 + *2/*4 + *1/*3 + *2/*5 + *2/*41 (assigned as normal metabolizer phenotype) .,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,CYP2D6 Intermediate Metabolizer
1447948592,PMID:16719544,CYP2D6.1.001; CYP2D6.4.001,gefitinib,nor,1,CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with increased concentrations of gefitinib in healthy individuals as compared to CYP2D6 *1/*4 + *1/*2 + *2/*4 + *1/*3 + *2/*5 + *2/*41 (assigned as normal metabolizer phenotype) .,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,CYP2D6 Intermediate Metabolizer
1447948592,PMID:16719544,CYP2D6.2.001; CYP2D6.5.001,gefitinib,nor,1,CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with increased concentrations of gefitinib in healthy individuals as compared to CYP2D6 *1/*4 + *1/*2 + *2/*4 + *1/*3 + *2/*5 + *2/*41 (assigned as normal metabolizer phenotype) .,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,CYP2D6 Intermediate Metabolizer
1447948127,PMID:26323212,CYP2D6.5.001; CYP2D6.10.001,gefitinib,de,0.25,"CYP2D6 *5/*10 (assigned as poor metabolizer phenotype) is associated with increased risk of Toxic liver disease when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *1/*14 + *2/*5 + *2/*10.",COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,CYP2D6 Intermediate Metabolizer
1447948494,PMID:21502555,CYP2D6.1.001; CYP2D6.10.001,gefitinib,de,1.25,CYP2D6 *1/*10 is associated with Toxic liver disease when treated with gefitinib in people with Adenocarcinoma.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,CYP2D6 Normal Metabolizer
1183622774,PMID:14499311,CYP2D6.10.001; CYP2D6.10.001,haloperidol,de,0.5,CYP2D6 *10/*10 is not associated with decreased metabolism of haloperidol as compared to CYP2D6 *1/*1 + *1/*10.,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CYP2D6 Intermediate Metabolizer
1447677736,PMID:12960748,CYP2D6.2.001; CYP2D6.2.001,haloperidol,de,2,CYP2D6 *2/*2 is associated with increased concentrations of haloperidol in people with Schizophrenia as compared to CYP2D6 *1/*1 + *1/*2.,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CYP2D6 Normal Metabolizer
1452151321,PMID:18346175,CYP2D6.4.001; CYP2D6.4.001,haloperidol,f,0,"CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CYP2D6 Poor Metabolizer
1452151189,PMID:18346175,CYP2D6.4.001; CYP2D6.6.001,haloperidol,f,0,"CYP2D6 *4/*6 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CYP2D6 Poor Metabolizer
1183630925,PMID:12746736,CYP2D6.1.001; CYP2D6.4.001,haloperidol,f,1,CYP2D6 *4/*4 is associated with decreased metabolism of haloperidol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*4.,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CYP2D6 Intermediate Metabolizer
1448261461,PMID:27469576,CYP2D6.6.001; CYP2D6.6.001,haloperidol,f,0,CYP2D6 *6/*6 is associated with adverse events and extrapyramidal symptoms when treated with ciprofloxacin and haloperidol.,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CYP2D6 Poor Metabolizer
1451152760,PMID:9352573,CYP2D6.1.001; CYP2D6.1.001,hydrocodone,nor,2,"CYP2D6 *3/*3 are associated with decreased risk of Opioid-Related Disorders due to codeine, hydrocodone or oxycodone as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.",CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=O)CC4,CYP2D6 Normal Metabolizer
1183617926,PMID:16631290,CYP2D6.4.001; CYP2D6.6.001,hydrocodone,f,0,CYP2D6 *4/*6 is associated with response to hydrocodone when treated with hydrocodone.,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=O)CC4,CYP2D6 Poor Metabolizer
1451152760,PMID:9352573,CYP2D6.4.001; CYP2D6.4.001,hydrocodone,f,0,"CYP2D6 *4/*4 are associated with decreased risk of Opioid-Related Disorders due to codeine, hydrocodone or oxycodone as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.",CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=O)CC4,CYP2D6 Poor Metabolizer
1449189944,PMID:20837591,CYP2D6.2.001; CYP2D6.41.001,hydrocodone,de,1.25,CYP2D6 *2/*41 is associated with increased concentrations of hydrocodone.,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=O)CC4,CYP2D6 Normal Metabolizer
1451152760,PMID:9352573,CYP2D6.1.001; CYP2D6.4.001,hydrocodone,nor,1,"CYP2D6 *3/*3 are associated with decreased risk of Opioid-Related Disorders due to codeine, hydrocodone or oxycodone as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.",CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=O)CC4,CYP2D6 Intermediate Metabolizer
1183617426,PMCID:PMC2291379,CYP2D6.4.001; CYP2D6.4.001,imipramine,f,0,"CYP2D6 *4/*4 is associated with decreased dose of amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.",CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Poor Metabolizer
1183684336,PMCID:PMC1365132,CYP2D6.5.001; CYP2D6.5.001,imipramine,f,0,CYP2D6 *5/*5 are associated with decreased metabolism of imipramine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Poor Metabolizer
1446902165,PMID:17667959,CYP2D6.4.001; CYP2D6.5.001,imipramine,f,0,"CYP2D6 *4/*5 (assigned as poor metabolizers phenotype) is associated with increased concentrations of desipramine and imipramine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.",CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Poor Metabolizer
1183617426,PMCID:PMC2291379,CYP2D6.1.001; CYP2D6.1.001,imipramine,nor,2,"CYP2D6 *4/*4 is associated with decreased dose of amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.",CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Normal Metabolizer
1446900845,PMID:9014200,CYP2D6.3.001; CYP2D6.5.001,imipramine,f,0,CYP2D6 *3/*5 (assigned as poor metabolizers phenotype) are associated with decreased metabolism of imipramine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*5 + *1/*3 + *1/*4.,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Poor Metabolizer
1183617426,PMCID:PMC2291379,CYP2D6.4.001; CYP2D6.4.001,maprotiline,f,0,"CYP2D6 *4/*4 is associated with decreased dose of amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.",CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24,CYP2D6 Poor Metabolizer
1450822217,PMID:30815856,CYP2D6.2.001; CYP2D6.10.001,mephedrone,de,1.25,CYP2D6 *2/*10 are associated with increased concentrations of mephedrone in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.,CC1=CC=C(C=C1)C(=O)C(C)NC,CYP2D6 Normal Metabolizer
1450822217,PMID:30815856,CYP2D6.1.001; CYP2D6.1.001,mephedrone,nor,2,CYP2D6 *1/*9 are associated with increased concentrations of mephedrone in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.,CC1=CC=C(C=C1)C(=O)C(C)NC,CYP2D6 Normal Metabolizer
1450822217,PMID:30815856,CYP2D6.2.001; CYP2D6.2.001,mephedrone,nor,2,CYP2D6 *1/*9 are associated with increased concentrations of mephedrone in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.,CC1=CC=C(C=C1)C(=O)C(C)NC,CYP2D6 Normal Metabolizer
1450822217,PMID:30815856,CYP2D6.1.001; CYP2D6.3.001,mephedrone,de,1,CYP2D6 *1/*3 are associated with increased concentrations of mephedrone in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.,CC1=CC=C(C=C1)C(=O)C(C)NC,CYP2D6 Intermediate Metabolizer
1450822217,PMID:30815856,CYP2D6.2.001; CYP2D6.4.001,mephedrone,de,1,CYP2D6 *2/*4 are associated with increased concentrations of mephedrone in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.,CC1=CC=C(C=C1)C(=O)C(C)NC,CYP2D6 Intermediate Metabolizer
1450822217,PMID:30815856,CYP2D6.1.001; CYP2D6.5.001,mephedrone,de,1,CYP2D6 *1/*5 are associated with increased concentrations of mephedrone in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.,CC1=CC=C(C=C1)C(=O)C(C)NC,CYP2D6 Intermediate Metabolizer
1450822217,PMID:30815856,CYP2D6.1.001; CYP2D6.41.001,mephedrone,de,1.25,CYP2D6 *1/*41 are associated with increased concentrations of mephedrone in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.,CC1=CC=C(C=C1)C(=O)C(C)NC,CYP2D6 Normal Metabolizer
1450822217,PMID:30815856,CYP2D6.1.001; CYP2D6.9.001,mephedrone,de,1.25,CYP2D6 *1/*9 are associated with increased concentrations of mephedrone in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.,CC1=CC=C(C=C1)C(=O)C(C)NC,CYP2D6 Normal Metabolizer
1450971020,PMID:29843110,CYP2D6.1.001; CYP2D6.1.001,methamphetamine,nor,2,CYP2D6 *4/*10 (assigned as intermediate metabolizers phenotype) are associated with increased concentrations of methamphetamine as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *2/*2 + *2/*4 + *2/*5 + *2/*10 (assigned as normal metabolizers phenotype) .,C[C@@H](CC1=CC=CC=C1)NC,CYP2D6 Normal Metabolizer
1450971020,PMID:29843110,CYP2D6.2.001; CYP2D6.5.001,methamphetamine,nor,1,CYP2D6 *4/*10 (assigned as intermediate metabolizers phenotype) are associated with increased concentrations of methamphetamine as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *2/*2 + *2/*4 + *2/*5 + *2/*10 (assigned as normal metabolizers phenotype) .,C[C@@H](CC1=CC=CC=C1)NC,CYP2D6 Intermediate Metabolizer
1450971020,PMID:29843110,CYP2D6.10.001; CYP2D6.10.001,methamphetamine,de,0.5,CYP2D6 *10/*10 (assigned as intermediate metabolizers phenotype) are associated with increased concentrations of methamphetamine as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *2/*2 + *2/*4 + *2/*5 + *2/*10 (assigned as normal metabolizers phenotype) .,C[C@@H](CC1=CC=CC=C1)NC,CYP2D6 Intermediate Metabolizer
1450971020,PMID:29843110,CYP2D6.2.001; CYP2D6.10.001,methamphetamine,nor,1.25,CYP2D6 *4/*10 (assigned as intermediate metabolizers phenotype) are associated with increased concentrations of methamphetamine as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *2/*2 + *2/*4 + *2/*5 + *2/*10 (assigned as normal metabolizers phenotype) .,C[C@@H](CC1=CC=CC=C1)NC,CYP2D6 Normal Metabolizer
1450971020,PMID:29843110,CYP2D6.10.001; CYP2D6.18.001,methamphetamine,de,0.25,CYP2D6 *10/*18 (assigned as intermediate metabolizers phenotype) are associated with increased concentrations of methamphetamine as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *2/*2 + *2/*4 + *2/*5 + *2/*10 (assigned as normal metabolizers phenotype) .,C[C@@H](CC1=CC=CC=C1)NC,CYP2D6 Intermediate Metabolizer
1450971020,PMID:29843110,CYP2D6.1.001; CYP2D6.2.001,methamphetamine,nor,2,CYP2D6 *4/*10 (assigned as intermediate metabolizers phenotype) are associated with increased concentrations of methamphetamine as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *2/*2 + *2/*4 + *2/*5 + *2/*10 (assigned as normal metabolizers phenotype) .,C[C@@H](CC1=CC=CC=C1)NC,CYP2D6 Normal Metabolizer
1450971020,PMID:29843110,CYP2D6.10.001; CYP2D6.36.001,methamphetamine,de,0.25,CYP2D6 *10/*36 (assigned as intermediate metabolizers phenotype) are associated with increased concentrations of methamphetamine as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *2/*2 + *2/*4 + *2/*5 + *2/*10 (assigned as normal metabolizers phenotype) .,C[C@@H](CC1=CC=CC=C1)NC,CYP2D6 Intermediate Metabolizer
1450971020,PMID:29843110,CYP2D6.1.001; CYP2D6.5.001,methamphetamine,nor,1,CYP2D6 *4/*10 (assigned as intermediate metabolizers phenotype) are associated with increased concentrations of methamphetamine as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *2/*2 + *2/*4 + *2/*5 + *2/*10 (assigned as normal metabolizers phenotype) .,C[C@@H](CC1=CC=CC=C1)NC,CYP2D6 Intermediate Metabolizer
1450971020,PMID:29843110,CYP2D6.2.001; CYP2D6.2.001,methamphetamine,nor,2,CYP2D6 *4/*10 (assigned as intermediate metabolizers phenotype) are associated with increased concentrations of methamphetamine as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *2/*2 + *2/*4 + *2/*5 + *2/*10 (assigned as normal metabolizers phenotype) .,C[C@@H](CC1=CC=CC=C1)NC,CYP2D6 Normal Metabolizer
1450971020,PMID:29843110,CYP2D6.5.001; CYP2D6.10.001,methamphetamine,de,0.25,CYP2D6 *5/*10 (assigned as intermediate metabolizers phenotype) are associated with increased concentrations of methamphetamine as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *2/*2 + *2/*4 + *2/*5 + *2/*10 (assigned as normal metabolizers phenotype) .,C[C@@H](CC1=CC=CC=C1)NC,CYP2D6 Intermediate Metabolizer
1450971020,PMID:29843110,CYP2D6.5.001; CYP2D6.14.001,methamphetamine,de,0.5,CYP2D6 *5/*14 (assigned as intermediate metabolizers phenotype) are associated with increased concentrations of methamphetamine as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *2/*2 + *2/*4 + *2/*5 + *2/*10 (assigned as normal metabolizers phenotype) .,C[C@@H](CC1=CC=CC=C1)NC,CYP2D6 Intermediate Metabolizer
1452196960,PMID:33247397,CYP2D6.1.001; CYP2D6.2.001,metoclopramide,nor,2,CYP2D6 *1/*10 is associated with decreased clearance of metoclopramide in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,CYP2D6 Normal Metabolizer
1452196960,PMID:33247397,CYP2D6.10.001; CYP2D6.10.001,metoclopramide,de,0.5,CYP2D6 *10/*10 is associated with decreased clearance of metoclopramide in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,CYP2D6 Intermediate Metabolizer
1452192742,PMID:37480318,CYP2D6.4.001; CYP2D6.4.001,metoclopramide,f,0,CYP2D6 *4/*4 (assigned as poor metabolizers) is associated with increased likelihood of adverse events when treated with metoclopramide.,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,CYP2D6 Poor Metabolizer
1452192742,PMID:37480318,CYP2D6.1.001; CYP2D6.5.001,metoclopramide,de,1,CYP2D6 *1/*5 (assigned as intermediate metabolizers phenotype) is associated with increased likelihood of adverse events when treated with metoclopramide.,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,CYP2D6 Intermediate Metabolizer
1452196960,PMID:33247397,CYP2D6.1.001; CYP2D6.1.001,metoclopramide,nor,2,CYP2D6 *1/*10 is associated with decreased clearance of metoclopramide in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,CYP2D6 Normal Metabolizer
1452196960,PMID:33247397,CYP2D6.5.001; CYP2D6.10.001,metoclopramide,de,0.25,CYP2D6 *5/*10 is associated with decreased clearance of metoclopramide in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,CYP2D6 Intermediate Metabolizer
1184085740,PMCID:PMC4111800,CYP2D6.3.001; CYP2D6.4.001,metoprolol,f,0,CYP2D6 *3/*4 are associated with greater heart rate (HR) reduction when treated with metoprolol as compared to CYP2D6 *1/*1.,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,CYP2D6 Poor Metabolizer
1184085740,PMCID:PMC4111800,CYP2D6.5.001; CYP2D6.10.001,metoprolol,de,0.25,CYP2D6 *5/*10 are associated with greater heart rate (HR) reduction when treated with metoprolol as compared to CYP2D6 *1/*1.,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,CYP2D6 Intermediate Metabolizer
1184085740,PMCID:PMC4111800,CYP2D6.3.001; CYP2D6.17.001,metoprolol,de,0.5,CYP2D6 *3/*17 are associated with greater heart rate (HR) reduction when treated with metoprolol as compared to CYP2D6 *1/*1.,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,CYP2D6 Intermediate Metabolizer
1184756913,PMID:11823760,CYP2D6.1.001; CYP2D6.1.001,metoprolol,nor,2,"CYP2D6 *5/*17 is associated with decreased metabolism of codeine, debrisoquine, dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *17/*17 + *1/*1.",CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,CYP2D6 Normal Metabolizer
1184000492,PMID:24193112,CYP2D6.4.001; CYP2D6.4.001,metoprolol,f,0,CYP2D6 *4/*4 are associated with increased plasma metoprolol concentrations when treated with metoprolol as compared to CYP2D6 *1/*1.,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,CYP2D6 Poor Metabolizer
1184756327,PMID:10471072,CYP2D6.4.001; CYP2D6.20.001,metoprolol,f,0,CYP2D6 *4/*20 (assigned as poor metabolizers phenotype) is associated with decreased enzyme activity of CYP2D6 when assayed with metoprolol.,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,CYP2D6 Poor Metabolizer
1184000492,PMID:24193112,CYP2D6.1.001; CYP2D6.4.001,metoprolol,de,1,CYP2D6 *1/*4 are associated with increased plasma metoprolol concentrations when treated with metoprolol as compared to CYP2D6 *1/*1.,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,CYP2D6 Intermediate Metabolizer
1184085740,PMCID:PMC4111800,CYP2D6.4.001; CYP2D6.10.001,metoprolol,de,0.25,CYP2D6 *4/*10 are associated with greater heart rate (HR) reduction when treated with metoprolol as compared to CYP2D6 *1/*1.,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,CYP2D6 Intermediate Metabolizer
1184085740,PMCID:PMC4111800,CYP2D6.4.001; CYP2D6.17.001,metoprolol,de,0.5,CYP2D6 *4/*17 are associated with greater heart rate (HR) reduction when treated with metoprolol as compared to CYP2D6 *1/*1.,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,CYP2D6 Intermediate Metabolizer
1184085740,PMCID:PMC4111800,CYP2D6.4.001; CYP2D6.6.001,metoprolol,f,0,CYP2D6 *4/*6 are associated with greater heart rate (HR) reduction when treated with metoprolol as compared to CYP2D6 *1/*1.,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,CYP2D6 Poor Metabolizer
1184756941,PMID:11823760,CYP2D6.29.001; CYP2D6.29.001,metoprolol,de,1,CYP2D6 *29/*29 is associated with decreased metabolism of dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,CYP2D6 Intermediate Metabolizer
1184085740,PMCID:PMC4111800,CYP2D6.4.001; CYP2D6.5.001,metoprolol,f,0,CYP2D6 *4/*5 are associated with greater heart rate (HR) reduction when treated with metoprolol as compared to CYP2D6 *1/*1.,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,CYP2D6 Poor Metabolizer
1184756913,PMID:11823760,CYP2D6.5.001; CYP2D6.17.001,metoprolol,de,0.5,"CYP2D6 *5/*17 is associated with decreased metabolism of codeine, debrisoquine, dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *17/*17 + *1/*1.",CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,CYP2D6 Intermediate Metabolizer
1444703011,PMID:9408809,CYP2D6.1.001; CYP2D6.1.001,mianserin,nor,2,CYP2D6 *1/*10 are associated with increased concentrations of mianserin in people with Depression as compared to CYP2D6 *1/*1.,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42,CYP2D6 Normal Metabolizer
1444703011,PMID:9408809,CYP2D6.1.001; CYP2D6.10.001,mianserin,de,1.25,CYP2D6 *1/*10 are associated with increased concentrations of mianserin in people with Depression as compared to CYP2D6 *1/*1.,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42,CYP2D6 Normal Metabolizer
1183618807,PMID:19429471,CYP2D6.4.001; CYP2D6.4.001,mirtazapine,f,0,CYP2D6 *4/*4 is associated with increased dose/weight adjusted AUC for mirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 *1/*1.,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CYP2D6 Poor Metabolizer
1183618754,PMID:22926595,CYP2D6.3.001; CYP2D6.4.001,mirtazapine,f,0,CYP2D6 *3/*4 are associated with increased S-mirtazapine plasma levels in non-smokers at day 14 of treatment when treated with mirtazapine in people with Depression as compared to CYP2D6 *1/*1.,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CYP2D6 Poor Metabolizer
1183618754,PMID:22926595,CYP2D6.1.001; CYP2D6.1.001,mirtazapine,nor,2,CYP2D6 *3/*4 are associated with increased S-mirtazapine plasma levels in non-smokers at day 14 of treatment when treated with mirtazapine in people with Depression as compared to CYP2D6 *1/*1.,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CYP2D6 Normal Metabolizer
1446904494,PMID:9585799,CYP2D6.1.001; CYP2D6.5.001,nortriptyline,de,1,CYP2D6 *1/*5 are associated with decreased metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2xN.,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Intermediate Metabolizer
1446902725,PMID:15590749,CYP2D6.2.001; CYP2D6.4.001,nortriptyline,de,1,"CYP2D6 *2/*4 are associated with increased concentrations of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.",CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Intermediate Metabolizer
1446904494,PMID:9585799,CYP2D6.1.001; CYP2D6.4.001,nortriptyline,de,1,CYP2D6 *1/*4 are associated with decreased metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2xN.,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Intermediate Metabolizer
1446902725,PMID:15590749,CYP2D6.2.001; CYP2D6.41.001,nortriptyline,nor,1.25,"CYP2D6 *2/*4 are associated with increased concentrations of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.",CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Normal Metabolizer
1446902725,PMID:15590749,CYP2D6.1.001; CYP2D6.2.001,nortriptyline,nor,2,"CYP2D6 *2/*4 are associated with increased concentrations of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.",CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Normal Metabolizer
1446902725,PMID:15590749,CYP2D6.4.001; CYP2D6.41.001,nortriptyline,de,0.25,"CYP2D6 *4/*41 are associated with increased concentrations of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.",CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Intermediate Metabolizer
1446902725,PMID:15590749,CYP2D6.2.001; CYP2D6.5.001,nortriptyline,de,1,"CYP2D6 *2/*5 are associated with increased concentrations of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.",CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Intermediate Metabolizer
1183617426,PMCID:PMC2291379,CYP2D6.4.001; CYP2D6.4.001,nortriptyline,f,0,"CYP2D6 *4/*4 is associated with decreased dose of amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.",CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Poor Metabolizer
1184468489,PMID:9797795,CYP2D6.1.001; CYP2D6.10.001,nortriptyline,nor,1.25,CYP2D6 *1/*10 is not associated with metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Normal Metabolizer
1446904589,PMID:23799451,CYP2D6.1.001; CYP2D6.81.001,nortriptyline,de,1,"CYP2D6 *1/*81 is associated with increased concentrations of nortriptyline in people with Depressive Disorder, Major.",CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Intermediate Metabolizer
1446902725,PMID:15590749,CYP2D6.1.001; CYP2D6.41.001,nortriptyline,nor,1.25,"CYP2D6 *2/*4 are associated with increased concentrations of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.",CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Normal Metabolizer
1183618387,PMID:11682257,CYP2D6.5.001; CYP2D6.10.001,nortriptyline,de,0.25,"CYP2D6 *5/*10 is associated with increased mean nortriptyline concentrations and nortriptyline concentrations per unit dose of the medication when treated with nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.",CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Intermediate Metabolizer
1184468498,PMID:9797795,CYP2D6.10.001; CYP2D6.10.001,nortriptyline,de,0.5,CYP2D6 *10/*10 is associated with decreased metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CYP2D6 Intermediate Metabolizer
1452151189,PMID:18346175,CYP2D6.4.001; CYP2D6.6.001,olanzapine,f,0,"CYP2D6 *4/*6 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,CYP2D6 Poor Metabolizer
1452151321,PMID:18346175,CYP2D6.1.001; CYP2D6.1.001,olanzapine,nor,2,"CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,CYP2D6 Normal Metabolizer
1183632031,PMID:11901361,CYP2D6.1.001; CYP2D6.4.001,olanzapine,de,1,CYP2D6 *1/*4 are associated with increased Weight gain when treated with olanzapine in men with Schizophrenia as compared to CYP2D6 *1/*1.,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,CYP2D6 Intermediate Metabolizer
1183632031,PMID:11901361,CYP2D6.1.001; CYP2D6.3.001,olanzapine,de,1,CYP2D6 *1/*3 are associated with increased Weight gain when treated with olanzapine in men with Schizophrenia as compared to CYP2D6 *1/*1.,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,CYP2D6 Intermediate Metabolizer
1452151189,PMID:18346175,CYP2D6.4.001; CYP2D6.5.001,olanzapine,f,0,"CYP2D6 *4/*5 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,CYP2D6 Poor Metabolizer
1452151321,PMID:18346175,CYP2D6.4.001; CYP2D6.4.001,olanzapine,f,0,"CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,CYP2D6 Poor Metabolizer
1183617426,PMCID:PMC2291379,CYP2D6.1.001; CYP2D6.1.001,opipramol,nor,2,"CYP2D6 *4/*4 is associated with decreased dose of amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.",C1CN(CCN1CCCN2C3=CC=CC=C3C=CC4=CC=CC=C42)CCO,CYP2D6 Normal Metabolizer
1184473395,PMCID:PMC3610662,CYP2D6.4.001; CYP2D6.7.001,oxycodone,f,0,CYP2D6 *4/*7 (assigned as poor metabolizer phenotype) is associated with decreased Mean oxymophone/oxycodone ratios when treated with oxycodone as compared to CYP2D6 *1/*1xN + *2/*2xN + *1xN/*2 (assigned as ultrarapid metabolizer phenotype) .,CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,CYP2D6 Poor Metabolizer
1451152760,PMID:9352573,CYP2D6.1.001; CYP2D6.3.001,oxycodone,de,1,"CYP2D6 *3/*3 are associated with decreased risk of Opioid-Related Disorders due to codeine, hydrocodone or oxycodone as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.",CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,CYP2D6 Intermediate Metabolizer
1184473395,PMCID:PMC3610662,CYP2D6.4.001; CYP2D6.5.001,oxycodone,f,0,CYP2D6 *4/*5 (assigned as poor metabolizer phenotype) is associated with decreased Mean oxymophone/oxycodone ratios when treated with oxycodone as compared to CYP2D6 *1/*1xN + *2/*2xN + *1xN/*2 (assigned as ultrarapid metabolizer phenotype) .,CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,CYP2D6 Poor Metabolizer
1183621831,PMID:19719813,CYP2D6.3.001; CYP2D6.4.001,oxycodone,f,0,CYP2D6 *3/*4 is associated with mean plasma concentration of oxymorphone and lower mean oxymorphone/oxycodone ratio when treated with oxycodone as compared to CYP2D6 *1/*1.,CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,CYP2D6 Poor Metabolizer
1451152760,PMID:9352573,CYP2D6.1.001; CYP2D6.1.001,oxycodone,nor,2,"CYP2D6 *3/*3 are associated with decreased risk of Opioid-Related Disorders due to codeine, hydrocodone or oxycodone as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.",CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,CYP2D6 Normal Metabolizer
1451152760,PMID:9352573,CYP2D6.3.001; CYP2D6.3.001,oxycodone,f,0,"CYP2D6 *3/*3 are associated with decreased risk of Opioid-Related Disorders due to codeine, hydrocodone or oxycodone as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.",CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,CYP2D6 Poor Metabolizer
1183621795,PMCID:PMC3249195,CYP2D6.2.001; CYP2D6.2.001,oxycodone,nor,2,CYP2D6 *4/*6 are associated with decreased serum concentrations of oxymorphone and noroxymorphone and oxymorphone/oxycodone ratios when treated with oxycodone in people with Neoplasms as compared to CYP2D6 *1/*1 + *2/*2.,CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,CYP2D6 Normal Metabolizer
1451152760,PMID:9352573,CYP2D6.4.001; CYP2D6.4.001,oxycodone,f,0,"CYP2D6 *4/*4 are associated with decreased risk of Opioid-Related Disorders due to codeine, hydrocodone or oxycodone as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.",CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,CYP2D6 Poor Metabolizer
1183620672,PMID:19743889,CYP2D6.1.001; CYP2D6.1.001,paroxetine,nor,2,CYP2D6 *1/*1 is associated with decreased paroxetine plasma concentrations increased during the course of pregnancy when treated with paroxetine in women.,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP2D6 Normal Metabolizer
1444712725,PMID:25967538,CYP2D6.1.001; CYP2D6.5.001,paroxetine,de,1,CYP2D6 *1/*5 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of paroxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *1/*41 + *2/*10 + *2/*14 (assigned as normal metabolizers phenotype) .,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP2D6 Intermediate Metabolizer
1183701674,PMID:10505591,CYP2D6.1.001; CYP2D6.3.001,paroxetine,de,1,CYP2D6 *1/*3 is associated with increased median paroxetine steady-state plasma concentration when treated with paroxetine in healthy individuals as compared to CYP2D6 *1/*1.,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP2D6 Intermediate Metabolizer
1451643140,PMID:34231053,CYP2D6.1.001; CYP2D6.2.001,paroxetine,nor,2,CYP2D6 *4/*5 (assigned as poor metabolizer genotypes phenotype) are not associated with response to paroxetine in women with Depression and Pregnancy as compared to CYP2D6 *1/*1 + *1/*2 + *1/*4 + *1/*9 + *1/*10 + *1/*41 + *2/*2 + *2/*4 + *2/*10 + *2/*41 (assigned as normal metabolizer genotype phenotype) .,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP2D6 Normal Metabolizer
1449310381,PMID:28933337,CYP2D6.10.001; CYP2D6.10.001,paroxetine,de,0.5,CYP2D6 *10/*10 are associated with decreased metabolism of paroxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10 + *1/*2 + *2/*10 + *2/*14.,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP2D6 Intermediate Metabolizer
1451643140,PMID:34231053,CYP2D6.2.001; CYP2D6.10.001,paroxetine,nor,1.25,CYP2D6 *4/*5 (assigned as poor metabolizer genotypes phenotype) are not associated with response to paroxetine in women with Depression and Pregnancy as compared to CYP2D6 *1/*1 + *1/*2 + *1/*4 + *1/*9 + *1/*10 + *1/*41 + *2/*2 + *2/*4 + *2/*10 + *2/*41 (assigned as normal metabolizer genotype phenotype) .,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP2D6 Normal Metabolizer
1451643140,PMID:34231053,CYP2D6.4.001; CYP2D6.5.001,paroxetine,f,0,CYP2D6 *4/*5 (assigned as poor metabolizer genotypes phenotype) are not associated with response to paroxetine in women with Depression and Pregnancy as compared to CYP2D6 *1/*1 + *1/*2 + *1/*4 + *1/*9 + *1/*10 + *1/*41 + *2/*2 + *2/*4 + *2/*10 + *2/*41 (assigned as normal metabolizer genotype phenotype) .,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP2D6 Poor Metabolizer
1451643140,PMID:34231053,CYP2D6.4.001; CYP2D6.41.001,paroxetine,f,0.25,CYP2D6 *4/*41 (assigned as intermediate metabolizer genotypes phenotype) are not associated with response to paroxetine in women with Depression and Pregnancy as compared to CYP2D6 *1/*1 + *1/*2 + *1/*4 + *1/*9 + *1/*10 + *1/*41 + *2/*2 + *2/*4 + *2/*10 + *2/*41 (assigned as normal metabolizer genotype phenotype) .,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP2D6 Intermediate Metabolizer
1449310381,PMID:28933337,CYP2D6.10.001; CYP2D6.14.001,paroxetine,de,0.75,CYP2D6 *10/*14 are associated with decreased metabolism of paroxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10 + *1/*2 + *2/*10 + *2/*14.,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP2D6 Intermediate Metabolizer
1451643140,PMID:34231053,CYP2D6.1.001; CYP2D6.10.001,paroxetine,nor,1.25,CYP2D6 *4/*5 (assigned as poor metabolizer genotypes phenotype) are not associated with response to paroxetine in women with Depression and Pregnancy as compared to CYP2D6 *1/*1 + *1/*2 + *1/*4 + *1/*9 + *1/*10 + *1/*41 + *2/*2 + *2/*4 + *2/*10 + *2/*41 (assigned as normal metabolizer genotype phenotype) .,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP2D6 Normal Metabolizer
1449310381,PMID:28933337,CYP2D6.5.001; CYP2D6.10.001,paroxetine,de,0.25,CYP2D6 *5/*10 are associated with decreased metabolism of paroxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10 + *1/*2 + *2/*10 + *2/*14.,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP2D6 Intermediate Metabolizer
1451643140,PMID:34231053,CYP2D6.2.001; CYP2D6.2.001,paroxetine,nor,2,CYP2D6 *4/*5 (assigned as poor metabolizer genotypes phenotype) are not associated with response to paroxetine in women with Depression and Pregnancy as compared to CYP2D6 *1/*1 + *1/*2 + *1/*4 + *1/*9 + *1/*10 + *1/*41 + *2/*2 + *2/*4 + *2/*10 + *2/*41 (assigned as normal metabolizer genotype phenotype) .,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP2D6 Normal Metabolizer
1451643140,PMID:34231053,CYP2D6.2.001; CYP2D6.4.001,paroxetine,nor,1,CYP2D6 *4/*5 (assigned as poor metabolizer genotypes phenotype) are not associated with response to paroxetine in women with Depression and Pregnancy as compared to CYP2D6 *1/*1 + *1/*2 + *1/*4 + *1/*9 + *1/*10 + *1/*41 + *2/*2 + *2/*4 + *2/*10 + *2/*41 (assigned as normal metabolizer genotype phenotype) .,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP2D6 Intermediate Metabolizer
1451643140,PMID:34231053,CYP2D6.4.001; CYP2D6.10.001,paroxetine,f,0.25,CYP2D6 *4/*10 (assigned as intermediate metabolizer genotypes phenotype) are not associated with response to paroxetine in women with Depression and Pregnancy as compared to CYP2D6 *1/*1 + *1/*2 + *1/*4 + *1/*9 + *1/*10 + *1/*41 + *2/*2 + *2/*4 + *2/*10 + *2/*41 (assigned as normal metabolizer genotype phenotype) .,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP2D6 Intermediate Metabolizer
1451643140,PMID:34231053,CYP2D6.1.001; CYP2D6.4.001,paroxetine,nor,1,CYP2D6 *4/*5 (assigned as poor metabolizer genotypes phenotype) are not associated with response to paroxetine in women with Depression and Pregnancy as compared to CYP2D6 *1/*1 + *1/*2 + *1/*4 + *1/*9 + *1/*10 + *1/*41 + *2/*2 + *2/*4 + *2/*10 + *2/*41 (assigned as normal metabolizer genotype phenotype) .,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP2D6 Intermediate Metabolizer
1451643140,PMID:34231053,CYP2D6.1.001; CYP2D6.41.001,paroxetine,nor,1.25,CYP2D6 *4/*5 (assigned as poor metabolizer genotypes phenotype) are not associated with response to paroxetine in women with Depression and Pregnancy as compared to CYP2D6 *1/*1 + *1/*2 + *1/*4 + *1/*9 + *1/*10 + *1/*41 + *2/*2 + *2/*4 + *2/*10 + *2/*41 (assigned as normal metabolizer genotype phenotype) .,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP2D6 Normal Metabolizer
1449310381,PMID:28933337,CYP2D6.2.001; CYP2D6.14.001,paroxetine,nor,1.5,CYP2D6 *5/*10 are associated with decreased metabolism of paroxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10 + *1/*2 + *2/*10 + *2/*14.,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP2D6 Normal Metabolizer
1183617434,PMCID:PMC2291379,CYP2D6.4.001; CYP2D6.4.001,paroxetine,f,0,"CYP2D6 *4/*4 is associated with decreased dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline in people with Depression as compared to CYP2D6 *1/*1.",C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP2D6 Poor Metabolizer
1184165796,PMID:18641553,CYP2D6.4.001; CYP2D6.6.001,paroxetine,f,0,"CYP2D6 *4/*6 is not associated with persistent response when treated with paroxetine in people with Depressive Disorder, Major.",C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CYP2D6 Poor Metabolizer
1447954876,PMCID:PMC4757974,CYP2D6.2.001; CYP2D6.4.001,primaquine,de,1,CYP2D6 *2/*4 is associated with decreased response to primaquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.,CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2,CYP2D6 Intermediate Metabolizer
1447954876,PMCID:PMC4757974,CYP2D6.2.001; CYP2D6.2.001,primaquine,nor,2,CYP2D6 *1/*4 is associated with decreased response to primaquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.,CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2,CYP2D6 Normal Metabolizer
1447954774,PMID:24088113,CYP2D6.5.001; CYP2D6.6.001,primaquine,f,0,CYP2D6 *5/*6 are associated with increased concentrations of primaquine in people with Malaria as compared to CYP2D6 *1/*1 + *1/*10 + *1/*4 + *1/*5 + *1/*41.,CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2,CYP2D6 Poor Metabolizer
1447954876,PMCID:PMC4757974,CYP2D6.10.001; CYP2D6.10.001,primaquine,de,0.5,CYP2D6 *10/*10 is associated with decreased response to primaquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.,CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2,CYP2D6 Intermediate Metabolizer
1447954876,PMCID:PMC4757974,CYP2D6.1.001; CYP2D6.9.001,primaquine,nor,1.25,CYP2D6 *1/*4 is associated with decreased response to primaquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.,CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2,CYP2D6 Normal Metabolizer
1447954876,PMCID:PMC4757974,CYP2D6.1.001; CYP2D6.4.001,primaquine,de,1,CYP2D6 *1/*4 is associated with decreased response to primaquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.,CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2,CYP2D6 Intermediate Metabolizer
1447954876,PMCID:PMC4757974,CYP2D6.41.001; CYP2D6.41.001,primaquine,de,0.5,CYP2D6 *41/*41 is associated with decreased response to primaquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.,CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2,CYP2D6 Intermediate Metabolizer
1447954876,PMCID:PMC4757974,CYP2D6.2.001; CYP2D6.41.001,primaquine,nor,1.25,CYP2D6 *1/*4 is associated with decreased response to primaquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.,CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2,CYP2D6 Normal Metabolizer
1447954774,PMID:24088113,CYP2D6.1.001; CYP2D6.1.001,primaquine,nor,2,CYP2D6 *4/*41 are associated with increased concentrations of primaquine in people with Malaria as compared to CYP2D6 *1/*1 + *1/*10 + *1/*4 + *1/*5 + *1/*41.,CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2,CYP2D6 Normal Metabolizer
1447954774,PMID:24088113,CYP2D6.1.001; CYP2D6.10.001,primaquine,nor,1.25,CYP2D6 *4/*41 are associated with increased concentrations of primaquine in people with Malaria as compared to CYP2D6 *1/*1 + *1/*10 + *1/*4 + *1/*5 + *1/*41.,CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2,CYP2D6 Normal Metabolizer
1447954774,PMID:24088113,CYP2D6.1.001; CYP2D6.5.001,primaquine,nor,1,CYP2D6 *4/*41 are associated with increased concentrations of primaquine in people with Malaria as compared to CYP2D6 *1/*1 + *1/*10 + *1/*4 + *1/*5 + *1/*41.,CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2,CYP2D6 Intermediate Metabolizer
1447954774,PMID:24088113,CYP2D6.4.001; CYP2D6.41.001,primaquine,de,0.25,CYP2D6 *4/*41 are associated with increased concentrations of primaquine in people with Malaria as compared to CYP2D6 *1/*1 + *1/*10 + *1/*4 + *1/*5 + *1/*41.,CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2,CYP2D6 Intermediate Metabolizer
1447954876,PMCID:PMC4757974,CYP2D6.2.001; CYP2D6.10.001,primaquine,nor,1.25,CYP2D6 *1/*4 is associated with decreased response to primaquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.,CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2,CYP2D6 Normal Metabolizer
1183681888,PMID:17986163,CYP2D6.1.001; CYP2D6.1.001,promethazine,nor,2,CYP2D6 *4/*4 is associated with akathisia when treated with promethazine in women.,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,CYP2D6 Poor Metabolizer
1450417472,PMID:14653957,CYP2D6.10.001; CYP2D6.10.001,propafenone,de,0.5,CYP2D6 *10/*10 is associated with decreased metabolism of propafenone in healthy individuals as compared to CYP2D6 *1/*10 + *1/*1.,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O,CYP2D6 Intermediate Metabolizer
1451294540,PMID:33203295,CYP2D6.5.001; CYP2D6.5.001,propafenone,f,0,CYP2D6 *5/*5 (assigned as poor metabolizers phenotype) is associated with increased concentrations of propafenone in people with Tachycardia as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2 + *1/*10 + *2/*10 + *10/*10 (assigned as intermediate metabolizer and normal metabolizer phenotype) .,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O,CYP2D6 Poor Metabolizer
1451294540,PMID:33203295,CYP2D6.2.001; CYP2D6.36.001,propafenone,de,1,CYP2D6 *2/*36 (assigned as poor metabolizers phenotype) is associated with increased concentrations of propafenone in people with Tachycardia as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2 + *1/*10 + *2/*10 + *10/*10 (assigned as intermediate metabolizer and normal metabolizer phenotype) .,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O,CYP2D6 Intermediate Metabolizer
1451294540,PMID:33203295,CYP2D6.1.001; CYP2D6.5.001,propafenone,de,1,CYP2D6 *1/*5 (assigned as poor metabolizers phenotype) is associated with increased concentrations of propafenone in people with Tachycardia as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2 + *1/*10 + *2/*10 + *10/*10 (assigned as intermediate metabolizer and normal metabolizer phenotype) .,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O,CYP2D6 Intermediate Metabolizer
1451294540,PMID:33203295,CYP2D6.1.001; CYP2D6.1.001,propafenone,nor,2,CYP2D6 *1/*5 (assigned as poor metabolizers phenotype) is associated with increased concentrations of propafenone in people with Tachycardia as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2 + *1/*10 + *2/*10 + *10/*10 (assigned as intermediate metabolizer and normal metabolizer phenotype) .,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O,CYP2D6 Normal Metabolizer
1451294540,PMID:33203295,CYP2D6.2.001; CYP2D6.2.001,propafenone,nor,2,CYP2D6 *1/*5 (assigned as poor metabolizers phenotype) is associated with increased concentrations of propafenone in people with Tachycardia as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2 + *1/*10 + *2/*10 + *10/*10 (assigned as intermediate metabolizer and normal metabolizer phenotype) .,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O,CYP2D6 Normal Metabolizer
1452151321,PMID:18346175,CYP2D6.1.001; CYP2D6.1.001,quetiapine,nor,2,"CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42,CYP2D6 Normal Metabolizer
1452151189,PMID:18346175,CYP2D6.4.001; CYP2D6.5.001,quetiapine,f,0,"CYP2D6 *4/*5 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42,CYP2D6 Poor Metabolizer
1452151189,PMID:18346175,CYP2D6.4.001; CYP2D6.6.001,quetiapine,f,0,"CYP2D6 *4/*6 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42,CYP2D6 Poor Metabolizer
1452151189,PMID:18346175,CYP2D6.3.001; CYP2D6.4.001,quetiapine,f,0,"CYP2D6 *3/*4 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42,CYP2D6 Poor Metabolizer
1448530382,PMID:26944100,CYP2D6.10.001; CYP2D6.41.001,risperidone,de,0.5,CYP2D6 *10/*41 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of risperidone in children as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *2/*10 + *1/*4 + *1/*5 + *2/*41 + *1/*41 (assigned as normal metabolizers phenotype) .,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP2D6 Intermediate Metabolizer
1448530382,PMID:26944100,CYP2D6.10.001; CYP2D6.10.001,risperidone,de,0.5,CYP2D6 *10/*10 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of risperidone in children as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *2/*10 + *1/*4 + *1/*5 + *2/*41 + *1/*41 (assigned as normal metabolizers phenotype) .,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP2D6 Intermediate Metabolizer
1448530382,PMID:26944100,CYP2D6.2.001; CYP2D6.41.001,risperidone,nor,1.25,CYP2D6 *10/*10 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of risperidone in children as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *2/*10 + *1/*4 + *1/*5 + *2/*41 + *1/*41 (assigned as normal metabolizers phenotype) .,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP2D6 Normal Metabolizer
1448530382,PMID:26944100,CYP2D6.2.001; CYP2D6.10.001,risperidone,nor,1.25,CYP2D6 *10/*10 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of risperidone in children as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *2/*10 + *1/*4 + *1/*5 + *2/*41 + *1/*41 (assigned as normal metabolizers phenotype) .,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP2D6 Normal Metabolizer
1452151189,PMID:18346175,CYP2D6.3.001; CYP2D6.4.001,risperidone,f,0,"CYP2D6 *3/*4 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP2D6 Poor Metabolizer
1452151321,PMID:18346175,CYP2D6.1.001; CYP2D6.1.001,risperidone,nor,2,"CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP2D6 Normal Metabolizer
1448530382,PMID:26944100,CYP2D6.1.001; CYP2D6.4.001,risperidone,nor,1,CYP2D6 *10/*10 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of risperidone in children as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *2/*10 + *1/*4 + *1/*5 + *2/*41 + *1/*41 (assigned as normal metabolizers phenotype) .,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP2D6 Intermediate Metabolizer
1452151189,PMID:18346175,CYP2D6.4.001; CYP2D6.6.001,risperidone,f,0,"CYP2D6 *4/*6 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP2D6 Poor Metabolizer
1452151189,PMID:18346175,CYP2D6.4.001; CYP2D6.5.001,risperidone,f,0,"CYP2D6 *4/*5 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP2D6 Poor Metabolizer
1448530382,PMID:26944100,CYP2D6.1.001; CYP2D6.10.001,risperidone,nor,1.25,CYP2D6 *10/*10 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of risperidone in children as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *2/*10 + *1/*4 + *1/*5 + *2/*41 + *1/*41 (assigned as normal metabolizers phenotype) .,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP2D6 Normal Metabolizer
1448530382,PMID:26944100,CYP2D6.1.001; CYP2D6.2.001,risperidone,nor,2,CYP2D6 *10/*10 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of risperidone in children as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *2/*10 + *1/*4 + *1/*5 + *2/*41 + *1/*41 (assigned as normal metabolizers phenotype) .,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP2D6 Normal Metabolizer
1448530486,PMID:26944100,CYP2D6.5.001; CYP2D6.10.001,risperidone,de,0.25,CYP2D6 *5/*10 are associated with decreased metabolism of risperidone in children as compared to CYP2D6 *1/*1 + *1/*2.,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CYP2D6 Intermediate Metabolizer
1446899027,PMID:9241659,CYP2D6.4.001; CYP2D6.5.001,sparteine,f,0,CYP2D6 *4/*5 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of debrisoquine or sparteine in healthy individuals.,C1CCN2C[C@@H]3C[C@H]([C@H]2C1)CN4[C@H]3CCCC4,CYP2D6 Poor Metabolizer
1184986233,PMID:9511177,CYP2D6.1.001; CYP2D6.2.001,sparteine,nor,2,CYP2D6 *4/*10 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of sparteine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.,C1CCN2C[C@@H]3C[C@H]([C@H]2C1)CN4[C@H]3CCCC4,CYP2D6 Normal Metabolizer
1184756116,PMID:8946471,CYP2D6.5.001; CYP2D6.18.001,sparteine,f,0,CYP2D6 *5/*18 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.,C1CCN2C[C@@H]3C[C@H]([C@H]2C1)CN4[C@H]3CCCC4,CYP2D6 Poor Metabolizer
1184986233,PMID:9511177,CYP2D6.5.001; CYP2D6.10.001,sparteine,de,0.25,CYP2D6 *5/*10 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of sparteine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.,C1CCN2C[C@@H]3C[C@H]([C@H]2C1)CN4[C@H]3CCCC4,CYP2D6 Intermediate Metabolizer
1184986233,PMID:9511177,CYP2D6.10.001; CYP2D6.10.001,sparteine,de,0.5,CYP2D6 *10/*10 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of sparteine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.,C1CCN2C[C@@H]3C[C@H]([C@H]2C1)CN4[C@H]3CCCC4,CYP2D6 Intermediate Metabolizer
1184986233,PMID:9511177,CYP2D6.4.001; CYP2D6.10.001,sparteine,de,0.25,CYP2D6 *4/*10 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of sparteine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.,C1CCN2C[C@@H]3C[C@H]([C@H]2C1)CN4[C@H]3CCCC4,CYP2D6 Intermediate Metabolizer
1184764284,PMID:9241659,CYP2D6.4.001; CYP2D6.12.001,sparteine,f,0,CYP2D6 *4/*12 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.,C1CCN2C[C@@H]3C[C@H]([C@H]2C1)CN4[C@H]3CCCC4,CYP2D6 Poor Metabolizer
1184755450,PMID:8530011,CYP2D6.5.001; CYP2D6.8.001,sparteine,f,0,CYP2D6 *5/*8 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of debrisoquine or sparteine in healthy individuals.,C1CCN2C[C@@H]3C[C@H]([C@H]2C1)CN4[C@H]3CCCC4,CYP2D6 Poor Metabolizer
1184764302,PMID:17001296,CYP2D6.4.001; CYP2D6.59.001,sparteine,de,0.5,CYP2D6 *4/*59 is associated with decreased metabolism of sparteine in healthy individuals.,C1CCN2C[C@@H]3C[C@H]([C@H]2C1)CN4[C@H]3CCCC4,CYP2D6 Intermediate Metabolizer
1447990337,PMID:2211621,CYP2D6.4.001; CYP2D6.4.001,sparteine,f,0,CYP2D6 *4/*4 are associated with decreased metabolism of debrisoquine or sparteine.,C1CCN2C[C@@H]3C[C@H]([C@H]2C1)CN4[C@H]3CCCC4,CYP2D6 Poor Metabolizer
1184764290,PMID:9241659,CYP2D6.4.001; CYP2D6.11.001,sparteine,f,0,CYP2D6 *4/*11 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.,C1CCN2C[C@@H]3C[C@H]([C@H]2C1)CN4[C@H]3CCCC4,CYP2D6 Poor Metabolizer
1184986212,PMID:9511177,CYP2D6.5.001; CYP2D6.7.001,sparteine,f,0,CYP2D6 *5/*7 (assigned as poor metabolizers phenotype) are associated with decreased metabolism of sparteine in healthy individuals.,C1CCN2C[C@@H]3C[C@H]([C@H]2C1)CN4[C@H]3CCCC4,CYP2D6 Poor Metabolizer
1446899019,PMID:9241659,CYP2D6.4.001; CYP2D6.6.001,sparteine,f,0,CYP2D6 *4/*6 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan or sparteine in healthy individuals.,C1CCN2C[C@@H]3C[C@H]([C@H]2C1)CN4[C@H]3CCCC4,CYP2D6 Poor Metabolizer
1447954841,PMCID:PMC4757974,CYP2D6.1.001; CYP2D6.2.001,tafenoquine,nor,2,CYP2D6 *4/*41 is not associated with decreased response to tafenoquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.,CC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC,CYP2D6 Normal Metabolizer
1447954841,PMCID:PMC4757974,CYP2D6.41.001; CYP2D6.41.001,tafenoquine,de,0.5,CYP2D6 *41/*41 is not associated with decreased response to tafenoquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.,CC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC,CYP2D6 Intermediate Metabolizer
1447954841,PMCID:PMC4757974,CYP2D6.10.001; CYP2D6.10.001,tafenoquine,de,0.5,CYP2D6 *10/*10 is not associated with decreased response to tafenoquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.,CC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC,CYP2D6 Intermediate Metabolizer
1447954841,PMCID:PMC4757974,CYP2D6.2.001; CYP2D6.10.001,tafenoquine,nor,1.25,CYP2D6 *4/*41 is not associated with decreased response to tafenoquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.,CC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC,CYP2D6 Normal Metabolizer
1447954841,PMCID:PMC4757974,CYP2D6.1.001; CYP2D6.1.001,tafenoquine,nor,2,CYP2D6 *4/*41 is not associated with decreased response to tafenoquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.,CC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC,CYP2D6 Normal Metabolizer
1447954841,PMCID:PMC4757974,CYP2D6.10.001; CYP2D6.41.001,tafenoquine,de,0.5,CYP2D6 *10/*41 is not associated with decreased response to tafenoquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.,CC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC,CYP2D6 Intermediate Metabolizer
1447954841,PMCID:PMC4757974,CYP2D6.1.001; CYP2D6.4.001,tafenoquine,de,1,CYP2D6 *1/*4 is not associated with decreased response to tafenoquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.,CC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC,CYP2D6 Intermediate Metabolizer
1447954841,PMCID:PMC4757974,CYP2D6.1.001; CYP2D6.9.001,tafenoquine,nor,1.25,CYP2D6 *4/*41 is not associated with decreased response to tafenoquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.,CC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC,CYP2D6 Normal Metabolizer
1447954841,PMCID:PMC4757974,CYP2D6.2.001; CYP2D6.41.001,tafenoquine,nor,1.25,CYP2D6 *4/*41 is not associated with decreased response to tafenoquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.,CC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC,CYP2D6 Normal Metabolizer
1447954841,PMCID:PMC4757974,CYP2D6.1.001; CYP2D6.10.001,tafenoquine,nor,1.25,CYP2D6 *4/*41 is not associated with decreased response to tafenoquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.,CC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC,CYP2D6 Normal Metabolizer
1447954841,PMCID:PMC4757974,CYP2D6.2.001; CYP2D6.2.001,tafenoquine,nor,2,CYP2D6 *4/*41 is not associated with decreased response to tafenoquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.,CC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC,CYP2D6 Normal Metabolizer
1444712127,PMID:16815318,CYP2D6.17.001; CYP2D6.41.001,tamoxifen,de,0.75,CYP2D6 *17/*41 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Intermediate Metabolizer
1452073007,PMID:37042388,CYP2D6.17.001; CYP2D6.29.001,tamoxifen,de,1,CYP2D6 *17/*29 (assigned as poor metabolizer phenotype) is associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2 (assigned as normal metabolizer phenotype) .,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Intermediate Metabolizer
1444711981,PMID:16815318,CYP2D6.4.001; CYP2D6.35.001,tamoxifen,de,1,CYP2D6 *35/*4 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *1/*1xN + *2/*1xN + *1/*2xN.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Intermediate Metabolizer
1444936127,PMID:17761971,CYP2D6.5.001; CYP2D6.5.001,tamoxifen,f,0,CYP2D6 *5/*5 are associated with decreased concentrations of 4-hydroxytamoxifen or endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Poor Metabolizer
1444711981,PMID:16815318,CYP2D6.2.001; CYP2D6.4.001,tamoxifen,de,1,CYP2D6 *2/*4 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *1/*1xN + *2/*1xN + *1/*2xN.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Intermediate Metabolizer
1444711981,PMID:16815318,CYP2D6.2.001; CYP2D6.41.001,tamoxifen,de,1.25,CYP2D6 *2/*41 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *1/*1xN + *2/*1xN + *1/*2xN.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Normal Metabolizer
1444709919,PMID:19189210,CYP2D6.1.001; CYP2D6.5.001,tamoxifen,de,1,CYP2D6 *1/*5 are associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in people with Breast Neoplasms as compared to CYP2D6 *3/*4 + *4/*9 + *9/*10 + *9/*41 + *41/*41 + *1/*4 + *1/*6 + *2/*4 + *2/*20 + *35/*4 + *1/*10 + *1/*9 + *1/*41 + *35/*10 + *2/*9 + *2/*41 + *35/*41 + *35/*9 + *1/*1 + *2/*2 + *1/*2 + *1/*35 + *1xN/*2.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Intermediate Metabolizer
1444697908,PMCID:PMC4356640,CYP2D6.4.001; CYP2D6.9.001,tamoxifen,f,0.25,CYP2D6 *4/*9 is associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *2/*2 + *1/*2 (assigned as normal metabolizers phenotype).,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Intermediate Metabolizer
1452073007,PMID:37042388,CYP2D6.17.001; CYP2D6.17.001,tamoxifen,de,1,CYP2D6 *17/*17 (assigned as poor metabolizer phenotype) is associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2 (assigned as normal metabolizer phenotype) .,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Intermediate Metabolizer
1450823459,PMID:30786012,CYP2D6.41.001; CYP2D6.41.001,tamoxifen,de,0.5,CYP2D6 *41/*41 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Intermediate Metabolizer
1448261067,PMID:26847054,CYP2D6.2.001; CYP2D6.9.001,tamoxifen,nor,1.25,CYP2D6 *3/*4 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*2xN + *1/*10 + *9/*41 + *2/*10 + *2/*2 + *1/*1xN + *1/*41 + *1/*9 + *1/*5 + *1/*4 + *10/*10 + *2/*4 + *2/*5 + *2/*41 + *2/*9.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Normal Metabolizer
1448261067,PMID:26847054,CYP2D6.10.001; CYP2D6.10.001,tamoxifen,nor,0.5,CYP2D6 *3/*4 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*2xN + *1/*10 + *9/*41 + *2/*10 + *2/*2 + *1/*1xN + *1/*41 + *1/*9 + *1/*5 + *1/*4 + *10/*10 + *2/*4 + *2/*5 + *2/*41 + *2/*9.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Intermediate Metabolizer
1444711981,PMID:16815318,CYP2D6.2.001; CYP2D6.35.001,tamoxifen,nor,2,CYP2D6 *2/*4 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *1/*1xN + *2/*1xN + *1/*2xN.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Normal Metabolizer
1445401203,PMCID:PMC2910688,CYP2D6.4.001; CYP2D6.4.001,tamoxifen,f,0,CYP2D6 *4/*4 are associated with decreased concentrations of 4-hydroxytamoxifen and endoxifen in women with as compared to CYP2D6 *1/*1.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Poor Metabolizer
1445401203,PMCID:PMC2910688,CYP2D6.4.001; CYP2D6.5.001,tamoxifen,f,0,CYP2D6 *4/*5 are associated with decreased concentrations of 4-hydroxytamoxifen and endoxifen in women with as compared to CYP2D6 *1/*1.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Poor Metabolizer
1444711981,PMID:16815318,CYP2D6.2.001; CYP2D6.10.001,tamoxifen,de,1.25,CYP2D6 *2/*10 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *1/*1xN + *2/*1xN + *1/*2xN.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Normal Metabolizer
1450823459,PMID:30786012,CYP2D6.9.001; CYP2D6.41.001,tamoxifen,de,0.5,CYP2D6 *9/*41 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Intermediate Metabolizer
1444933926,PMCID:PMC3548984,CYP2D6.3.001; CYP2D6.3.001,tamoxifen,f,0,CYP2D6 *3/*3 are associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Poor Metabolizer
1444713029,PMID:20515869,CYP2D6.3.001; CYP2D6.5.001,tamoxifen,f,0,CYP2D6 *3/*5 (assigned as poor metabolizers phenotype) are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *35/*35 + *1/*1xN + *2/*1xN + *1/*2xN.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Poor Metabolizer
1448261067,PMID:26847054,CYP2D6.1.001; CYP2D6.9.001,tamoxifen,nor,1.25,CYP2D6 *3/*4 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*2xN + *1/*10 + *9/*41 + *2/*10 + *2/*2 + *1/*1xN + *1/*41 + *1/*9 + *1/*5 + *1/*4 + *10/*10 + *2/*4 + *2/*5 + *2/*41 + *2/*9.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Normal Metabolizer
1444711981,PMID:16815318,CYP2D6.3.001; CYP2D6.35.001,tamoxifen,de,1,CYP2D6 *35/*5 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *1/*1xN + *2/*1xN + *1/*2xN.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Intermediate Metabolizer
1444711981,PMID:16815318,CYP2D6.35.001; CYP2D6.41.001,tamoxifen,de,1.25,CYP2D6 *35/*41 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *1/*1xN + *2/*1xN + *1/*2xN.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Normal Metabolizer
1444713029,PMID:20515869,CYP2D6.4.001; CYP2D6.6.001,tamoxifen,f,0,CYP2D6 *4/*6 (assigned as poor metabolizers phenotype) are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *35/*35 + *1/*1xN + *2/*1xN + *1/*2xN.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Poor Metabolizer
1444709919,PMID:19189210,CYP2D6.4.001; CYP2D6.41.001,tamoxifen,de,0.25,CYP2D6 *4/*41 are associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in people with Breast Neoplasms as compared to CYP2D6 *3/*4 + *4/*9 + *9/*10 + *9/*41 + *41/*41 + *1/*4 + *1/*6 + *2/*4 + *2/*20 + *35/*4 + *1/*10 + *1/*9 + *1/*41 + *35/*10 + *2/*9 + *2/*41 + *35/*41 + *35/*9 + *1/*1 + *2/*2 + *1/*2 + *1/*35 + *1xN/*2.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Intermediate Metabolizer
1444706217,PMID:20309015,CYP2D6.4.001; CYP2D6.7.001,tamoxifen,f,0,CYP2D6 *4/*7 (assigned as poor metabolizers phenotype) are associated with increased likelihood of Breast Neoplasms when treated with tamoxifen in women.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Poor Metabolizer
1444934738,PMCID:PMC1143572,CYP2D6.1.001; CYP2D6.4.001,tamoxifen,de,1,CYP2D6 *1/*4 are associated with increased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Intermediate Metabolizer
1444711981,PMID:16815318,CYP2D6.1.001; CYP2D6.3.001,tamoxifen,de,1,CYP2D6 *1/*3 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *1/*1xN + *2/*1xN + *1/*2xN.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Intermediate Metabolizer
1450823445,PMID:30786012,CYP2D6.1.001; CYP2D6.6.001,tamoxifen,de,1,CYP2D6 *1/*6 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Intermediate Metabolizer
1448261067,PMID:26847054,CYP2D6.1.001; CYP2D6.41.001,tamoxifen,nor,1.25,CYP2D6 *3/*4 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*2xN + *1/*10 + *9/*41 + *2/*10 + *2/*2 + *1/*1xN + *1/*41 + *1/*9 + *1/*5 + *1/*4 + *10/*10 + *2/*4 + *2/*5 + *2/*41 + *2/*9.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Normal Metabolizer
1452073007,PMID:37042388,CYP2D6.1.001; CYP2D6.2.001,tamoxifen,nor,2,CYP2D6 *17/*29 (assigned as poor metabolizer phenotype) is associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2 (assigned as normal metabolizer phenotype) .,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Normal Metabolizer
1448260990,PMCID:PMC4522133,CYP2D6.2.001; CYP2D6.3.001,tamoxifen,de,1,CYP2D6 *2/*3 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*2 + *1/*1 + *2/*2.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Intermediate Metabolizer
1452073007,PMID:37042388,CYP2D6.2.001; CYP2D6.2.001,tamoxifen,nor,2,CYP2D6 *17/*29 (assigned as poor metabolizer phenotype) is associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2 (assigned as normal metabolizer phenotype) .,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Normal Metabolizer
1444709919,PMID:19189210,CYP2D6.2.001; CYP2D6.5.001,tamoxifen,de,1,CYP2D6 *2/*5 are associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in people with Breast Neoplasms as compared to CYP2D6 *3/*4 + *4/*9 + *9/*10 + *9/*41 + *41/*41 + *1/*4 + *1/*6 + *2/*4 + *2/*20 + *35/*4 + *1/*10 + *1/*9 + *1/*41 + *35/*10 + *2/*9 + *2/*41 + *35/*41 + *35/*9 + *1/*1 + *2/*2 + *1/*2 + *1/*35 + *1xN/*2.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Intermediate Metabolizer
1444711981,PMID:16815318,CYP2D6.10.001; CYP2D6.35.001,tamoxifen,de,1.25,CYP2D6 *35/*10 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *1/*1xN + *2/*1xN + *1/*2xN.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Normal Metabolizer
1448261019,PMCID:PMC4522133,CYP2D6.4.001; CYP2D6.17.001,tamoxifen,f,0.5,CYP2D6 *4/*17 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*2 + *1/*1 + *2/*2.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Intermediate Metabolizer
1444934955,PMCID:PMC3726442,CYP2D6.3.001; CYP2D6.9.001,tamoxifen,f,0.25,CYP2D6 *3/*9 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9 + *1/*17 + *1/*41.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Intermediate Metabolizer
1444930388,PMCID:PMC3584248,CYP2D6.5.001; CYP2D6.10.001,tamoxifen,de,0.25,CYP2D6 *5/*10 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Intermediate Metabolizer
1448261019,PMCID:PMC4522133,CYP2D6.5.001; CYP2D6.41.001,tamoxifen,f,0.25,CYP2D6 *5/*41 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*2 + *1/*1 + *2/*2.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Intermediate Metabolizer
1448261019,PMCID:PMC4522133,CYP2D6.4.001; CYP2D6.10.001,tamoxifen,f,0.25,CYP2D6 *4/*10 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*2 + *1/*1 + *2/*2.,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CYP2D6 Intermediate Metabolizer
1183690112,PMID:16315032,CYP2D6.4.001; CYP2D6.5.001,timolol,f,0,"CYP2D6 *5/*4 is associated with increased exposure to timolol (higher area-under-curve, longer elimination half-lives ) when exposed to timolol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.",CC(C)(C)NC[C@@H](COC1=NSN=C1N2CCOCC2)O,CYP2D6 Poor Metabolizer
1183690112,PMID:16315032,CYP2D6.3.001; CYP2D6.3.001,timolol,f,0,"CYP2D6 *3/*3 is associated with increased exposure to timolol (higher area-under-curve, longer elimination half-lives ) when exposed to timolol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.",CC(C)(C)NC[C@@H](COC1=NSN=C1N2CCOCC2)O,CYP2D6 Poor Metabolizer
1183690112,PMID:16315032,CYP2D6.1.001; CYP2D6.1.001,timolol,nor,2,"CYP2D6 *3/*3 is associated with increased exposure to timolol (higher area-under-curve, longer elimination half-lives ) when exposed to timolol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.",CC(C)(C)NC[C@@H](COC1=NSN=C1N2CCOCC2)O,CYP2D6 Normal Metabolizer
1183690112,PMID:16315032,CYP2D6.4.001; CYP2D6.4.001,timolol,f,0,"CYP2D6 *4/*4 is associated with increased exposure to timolol (higher area-under-curve, longer elimination half-lives ) when exposed to timolol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.",CC(C)(C)NC[C@@H](COC1=NSN=C1N2CCOCC2)O,CYP2D6 Poor Metabolizer
1451157780,PMID:18317231,CYP2D6.4.001; CYP2D6.10.001,tramadol,de,0.25,CYP2D6 *4/*10 are associated with decreased metabolism of tramadol in infants as compared to CYP2D6 *1/*1.,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CYP2D6 Intermediate Metabolizer
1451565700,PMID:33131142,CYP2D6.1.001; CYP2D6.1.001,tramadol,nor,2,CYP2D6 *1/*5 are associated with increased concentrations of n-desmethyltramadol in people with Head and Neck Neoplasms as compared to CYP2D6 *1/*1 + *1/*2.,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CYP2D6 Normal Metabolizer
1451154280,PMID:12191703,CYP2D6.10.001; CYP2D6.17.001,tramadol,de,0.75,CYP2D6*10/*17 are associated with decreased clearance of tramadol as compared to CYP2D6 *1/*1.,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CYP2D6 Intermediate Metabolizer
1451208380,PMID:26926096,CYP2D6.4.001; CYP2D6.4.001,tramadol,f,0,CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) are associated with decreased concentrations of o-desmethyltramadol as compared to CYP2D6 *1/*1 + *1/*4 + *1/*6 + *1/*10 + *4/*10 + *10/*10.,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CYP2D6 Poor Metabolizer
1451141860,PMCID:PMC6960206,CYP2D6.5.001; CYP2D6.17.001,tramadol,de,0.5,CYP2D6 *5/*17 is associated with decreased response to hydrocodone or tramadol in women.,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CYP2D6 Intermediate Metabolizer
1451157780,PMID:18317231,CYP2D6.3.001; CYP2D6.3.001,tramadol,de,0,CYP2D6 *3/*3 are associated with decreased metabolism of tramadol in infants as compared to CYP2D6 *1/*1.,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CYP2D6 Poor Metabolizer
1451208260,PMID:25989235,CYP2D6.1.001; CYP2D6.3.001,tramadol,de,1,"CYP2D6 *1/*3 (assigned as intermediate metabolizer phenotype) are associated with increased risk of sedation when treated with ketoprofen and tramadol in people with Pain, Postoperative as compared to CYP2D6 *1/*1 + *1/*2 + *1/*9 + *1/*10 + *1/*17 + *1/*41 + *2/*2 (assigned as normal metabolizer phenotype) .",CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CYP2D6 Intermediate Metabolizer
1451565700,PMID:33131142,CYP2D6.5.001; CYP2D6.10.001,tramadol,de,0.25,CYP2D6 *5/*10 are associated with increased concentrations of n-desmethyltramadol in people with Head and Neck Neoplasms as compared to CYP2D6 *1/*1 + *1/*2.,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CYP2D6 Intermediate Metabolizer
1451229484,PMID:29524157,CYP2D6.5.001; CYP2D6.5.001,tramadol,f,0,"CYP2D6 *5/*5 are associated with decreased concentrations of n,o-didesmethyltramadol or o-desmethyltramadol in healthy individuals as compared to CYP2D6 *1 + *2.",CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CYP2D6 Poor Metabolizer
1451157780,PMID:18317231,CYP2D6.5.001; CYP2D6.41.001,tramadol,de,0.25,CYP2D6 *5/*41 are associated with decreased metabolism of tramadol in infants as compared to CYP2D6 *1/*1.,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CYP2D6 Intermediate Metabolizer
1451565700,PMID:33131142,CYP2D6.1.001; CYP2D6.10.001,tramadol,de,1.25,CYP2D6 *1/*10 are associated with increased concentrations of n-desmethyltramadol in people with Head and Neck Neoplasms as compared to CYP2D6 *1/*1 + *1/*2.,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CYP2D6 Normal Metabolizer
1451208260,PMID:25989235,CYP2D6.4.001; CYP2D6.41.001,tramadol,de,0.25,"CYP2D6 *4/*41 (assigned as intermediate metabolizer phenotype) are associated with increased risk of sedation when treated with ketoprofen and tramadol in people with Pain, Postoperative as compared to CYP2D6 *1/*1 + *1/*2 + *1/*9 + *1/*10 + *1/*17 + *1/*41 + *2/*2 (assigned as normal metabolizer phenotype) .",CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CYP2D6 Intermediate Metabolizer
1451208260,PMID:25989235,CYP2D6.41.001; CYP2D6.41.001,tramadol,de,0.5,"CYP2D6 *41/*41 (assigned as intermediate metabolizer phenotype) are associated with increased risk of sedation when treated with ketoprofen and tramadol in people with Pain, Postoperative as compared to CYP2D6 *1/*1 + *1/*2 + *1/*9 + *1/*10 + *1/*17 + *1/*41 + *2/*2 (assigned as normal metabolizer phenotype) .",CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CYP2D6 Intermediate Metabolizer
1183617913,PMID:16631290,CYP2D6.4.001; CYP2D6.6.001,tramadol,f,0,CYP2D6 *4/*6 is associated with intolerance to oxycodone and tramadol ( significant side effects as well as no pain relief) when treated with oxycodone and tramadol.,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CYP2D6 Poor Metabolizer
1451565700,PMID:33131142,CYP2D6.2.001; CYP2D6.5.001,tramadol,de,1,CYP2D6 *2/*5 are associated with increased concentrations of n-desmethyltramadol in people with Head and Neck Neoplasms as compared to CYP2D6 *1/*1 + *1/*2.,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CYP2D6 Intermediate Metabolizer
1183618142,PMID:20456744,CYP2D6.2.001; CYP2D6.2.001,tramadol,nor,2,CYP2D6 *2/*2 is not associated with decreased tramadol clearance in Chinese volunteers when treated with tramadol in healthy individuals as compared to CYP2D6 *1/*1.,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CYP2D6 Normal Metabolizer
1451565700,PMID:33131142,CYP2D6.10.001; CYP2D6.10.001,tramadol,de,0.5,CYP2D6 *10/*10 are associated with increased concentrations of n-desmethyltramadol in people with Head and Neck Neoplasms as compared to CYP2D6 *1/*1 + *1/*2.,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CYP2D6 Intermediate Metabolizer
1451208260,PMID:25989235,CYP2D6.1.001; CYP2D6.6.001,tramadol,de,1,"CYP2D6 *1/*6 (assigned as intermediate metabolizer phenotype) are associated with increased risk of sedation when treated with ketoprofen and tramadol in people with Pain, Postoperative as compared to CYP2D6 *1/*1 + *1/*2 + *1/*9 + *1/*10 + *1/*17 + *1/*41 + *2/*2 (assigned as normal metabolizer phenotype) .",CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CYP2D6 Intermediate Metabolizer
1451208260,PMID:25989235,CYP2D6.1.001; CYP2D6.17.001,tramadol,nor,1.5,"CYP2D6 *1/*3 (assigned as intermediate metabolizer phenotype) are associated with increased risk of sedation when treated with ketoprofen and tramadol in people with Pain, Postoperative as compared to CYP2D6 *1/*1 + *1/*2 + *1/*9 + *1/*10 + *1/*17 + *1/*41 + *2/*2 (assigned as normal metabolizer phenotype) .",CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CYP2D6 Normal Metabolizer
1451208260,PMID:25989235,CYP2D6.1.001; CYP2D6.4.001,tramadol,de,1,"CYP2D6 *1/*4 (assigned as intermediate metabolizer phenotype) are associated with increased risk of sedation when treated with ketoprofen and tramadol in people with Pain, Postoperative as compared to CYP2D6 *1/*1 + *1/*2 + *1/*9 + *1/*10 + *1/*17 + *1/*41 + *2/*2 (assigned as normal metabolizer phenotype) .",CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CYP2D6 Intermediate Metabolizer
1451565700,PMID:33131142,CYP2D6.2.001; CYP2D6.10.001,tramadol,de,1.25,CYP2D6 *2/*10 are associated with increased concentrations of n-desmethyltramadol in people with Head and Neck Neoplasms as compared to CYP2D6 *1/*1 + *1/*2.,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CYP2D6 Normal Metabolizer
1451208380,PMID:26926096,CYP2D6.3.001; CYP2D6.4.001,tramadol,f,0,CYP2D6 *3/*4 (assigned as poor metabolizer phenotype) are associated with decreased concentrations of o-desmethyltramadol as compared to CYP2D6 *1/*1 + *1/*4 + *1/*6 + *1/*10 + *4/*10 + *10/*10.,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CYP2D6 Poor Metabolizer
1446901857,PMID:14646691,CYP2D6.3.001; CYP2D6.5.001,trimipramine,f,0,CYP2D6 *3/*5 (assigned as poor metabolizers phenotype) are associated with decreased metabolism of trimipramine in healthy individuals as compared to CYP2D6 *1/*2xN.,CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C,CYP2D6 Poor Metabolizer
1446901857,PMID:14646691,CYP2D6.4.001; CYP2D6.4.001,trimipramine,f,0,CYP2D6 *4/*4 (assigned as poor metabolizers phenotype) are associated with decreased metabolism of trimipramine in healthy individuals as compared to CYP2D6 *1/*2xN.,CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C,CYP2D6 Poor Metabolizer
1446901857,PMID:14646691,CYP2D6.1.001; CYP2D6.1.001,trimipramine,nor,2,CYP2D6 *3/*3 (assigned as poor metabolizers phenotype) are associated with decreased metabolism of trimipramine in healthy individuals as compared to CYP2D6 *1/*2xN.,CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C,CYP2D6 Poor Metabolizer
1447148415,PMID:12728290,CYP2D6.1.001; CYP2D6.10.001,tropisetron,nor,1.25,CYP2D6 *1/*10 is associated with decreased metabolism of tropisetron in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43,CYP2D6 Normal Metabolizer
981954738,PMID:12065557,CYP2D6.3.001; CYP2D6.3.001,tropisetron,f,0,CYP2D6 *3/*3 is associated with decreased metabolism of tropisetron in people with Neoplasms.,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43,CYP2D6 Poor Metabolizer
1447148415,PMID:12728290,CYP2D6.1.001; CYP2D6.1.001,tropisetron,nor,2,CYP2D6 *1/*10 is associated with decreased metabolism of tropisetron in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43,CYP2D6 Normal Metabolizer
1447148428,PMID:12728290,CYP2D6.10.001; CYP2D6.10.001,tropisetron,de,0.5,CYP2D6 *10/*10 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of tropisetron in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43,CYP2D6 Intermediate Metabolizer
1184468657,PMID:17803873,CYP2D6.4.001; CYP2D6.10.001,venlafaxine,de,0.25,"CYP2D6 *4/*10 are associated with decreased dose of venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.",CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,CYP2D6 Intermediate Metabolizer
1183617359,PMID:16044105,CYP2D6.3.001; CYP2D6.4.001,venlafaxine,f,0,CYP2D6 *3/*4 are associated with decreased metabolism of venlafaxine as compared to CYP2D6 *1/*1.,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,CYP2D6 Poor Metabolizer
982029646,PMCID:PMC2014246,CYP2D6.5.001; CYP2D6.10.001,venlafaxine,de,0.25,CYP2D6 *5/*10 is associated with increased venlafaxine Cmax and AUC when treated with venlafaxine in healthy individuals as compared to CYP2D6 *1/*1.,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,CYP2D6 Intermediate Metabolizer
1184468657,PMID:17803873,CYP2D6.4.001; CYP2D6.17.001,venlafaxine,de,0.5,"CYP2D6 *4/*17 are associated with decreased dose of venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.",CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,CYP2D6 Intermediate Metabolizer
1452022080,PMID:25082493,CYP2D6.4.001; CYP2D6.4.001,venlafaxine,f,0,CYP2D6 *4/*4 is associated with increased likelihood of Serotonin Syndrome when treated with venlafaxine in people with Depression.,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,CYP2D6 Poor Metabolizer
1184468657,PMID:17803873,CYP2D6.3.001; CYP2D6.9.001,venlafaxine,de,0.25,"CYP2D6 *3/*9 are associated with decreased dose of venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.",CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,CYP2D6 Intermediate Metabolizer
982029525,PMID:18214456,CYP2D6.1.001; CYP2D6.5.001,venlafaxine,de,1,"CYP2D6 *1/*5 (assigned as intermediate metabolizer phenotype) is associated with decreased metabolism of venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.",CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,CYP2D6 Intermediate Metabolizer
1184468657,PMID:17803873,CYP2D6.4.001; CYP2D6.41.001,venlafaxine,de,0.25,"CYP2D6 *4/*41 are associated with decreased dose of venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.",CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,CYP2D6 Intermediate Metabolizer
982015073,PMID:16958828,CYP2D6.6.001; CYP2D6.6.001,venlafaxine,f,0,"CYP2D6 *6/*6 are associated with increased risk of side effects when treated with venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.",CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,CYP2D6 Poor Metabolizer
1447950037,PMID:25510856,CYP2D6.1.001; CYP2D6.1.001,venlafaxine,nor,2,CYP2D6 *10/*10 is associated with increased concentrations of venlafaxine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,CYP2D6 Normal Metabolizer
982015073,PMID:16958828,CYP2D6.4.001; CYP2D6.6.001,venlafaxine,f,0,"CYP2D6 *6/*4 are associated with increased risk of side effects when treated with venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.",CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,CYP2D6 Poor Metabolizer
982029604,PMID:10877013,CYP2D6.1.001; CYP2D6.10.001,venlafaxine,de,1.25,CYP2D6 *1/*10 is associated with increased Cmax and AUC of venlafaxine when treated with venlafaxine in healthy individuals as compared to CYP2D6 *1/*1.,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,CYP2D6 Normal Metabolizer
1447950037,PMID:25510856,CYP2D6.10.001; CYP2D6.10.001,venlafaxine,de,0.5,CYP2D6 *10/*10 is associated with increased concentrations of venlafaxine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,CYP2D6 Intermediate Metabolizer
1451888600,PMID:35703273,CYP2D6.4.001; CYP2D6.4.001,vortioxetine,f,0,CYP2D6 *4/*4 is associated with increased concentrations of vortioxetine as compared to CYP2D6 *1/*1.,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,CYP2D6 Poor Metabolizer
1451888600,PMID:35703273,CYP2D6.4.001; CYP2D6.10.001,vortioxetine,de,0.25,CYP2D6 *4/*10 is associated with increased concentrations of vortioxetine as compared to CYP2D6 *1/*1.,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,CYP2D6 Intermediate Metabolizer
1451430400,PMID:12107620,CYP2D6.1.001; CYP2D6.4.001,zuclopenthixol,de,1,CYP2D6 *1/*4 are associated with decreased metabolism of zuclopenthixol in people with Schizophrenia as compared to CYP2D6 *1/*1.,C1CN(CCN1CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,CYP2D6 Intermediate Metabolizer
1452151189,PMID:18346175,CYP2D6.4.001; CYP2D6.6.001,zuclopenthixol,f,0,"CYP2D6 *4/*6 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",C1CN(CCN1CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,CYP2D6 Poor Metabolizer
1452151189,PMID:18346175,CYP2D6.4.001; CYP2D6.5.001,zuclopenthixol,f,0,"CYP2D6 *4/*5 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",C1CN(CCN1CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,CYP2D6 Poor Metabolizer
1452151321,PMID:18346175,CYP2D6.1.001; CYP2D6.1.001,zuclopenthixol,nor,2,"CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .",C1CN(CCN1CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,CYP2D6 Normal Metabolizer
